US Pat. No. 10,428,465

HIGH STRENGTH AND LOW STIFFNESS AGAVE TISSUE

KIMBERLY-CLARK WORLDWIDE,...

18. A method of making a tissue web comprising the steps of:a. forming an aqueous suspension of high yield agave pulp fibers;
b. depositing an aqueous suspension of high yield agave pulp fibers onto a forming fabric;
c. dewatering the web to a consistency of about 20 percent or greater;
d. transferring the web to a throughdrying fabric
e. throughdrying the web, wherein the web comprises at least about 10 percent, by weight of the tissue web, high yield agave pulp fibers, and;
f. converting the web to a rolled tissue product, the product having a geometric mean tensile (GMT) from about 600 to about 1,200 g/3?, a Stiffness Index less than about 10.0 and a sheet bulk greater than about 10 cc/g.
US Pat. No. 10,426,163

BACTERICIDAL METHOD OF USING COMPOUNDS OF FATTY ACIDS AND AMMONIUM FATTY ACID SALTS

Falcon Lab, LLC, Wilming...

13. A method of disinfecting a bacterial contaminated surface comprising applying onto the surface a bactericidally effective amount of a solid compound of the structural formula (I):CH3(CH2)xCOOH.CH3(CH2)xCOO?NH4+  (I)wherein x is from 6 to 8.
US Pat. No. 10,427,187

MIXER SYSTEM FOR PRODUCING TOPCOAT COMPOSITIONS AND COATING COMPOSITIONS USED AS FILLER

BASF COATINGS GmbH, Muen...

1. A mixer system comprising a volumetric or gravimetric metering plant as a mixing apparatus and comprising at least the following components (a) to (d) and also optionally (e):(a) at least one pigment-free component (a) for producing at least one topcoat composition (A), with (a) comprising at least one binder (a1) and at least one organic solvent (a2) and optionally at least one matting agent (a3),
(b) at least one component (b), different from (a), for producing at least one coating composition (B) used as filling compound, where (b) comprises at least one binder (b1), at least one organic solvent (b2), and at least one filler (b3), where the binder (b1) comprises at least one unsaturated polyester and/or at least one polyurethane,
(c) a plurality of different pigment pastes different from the components (a), (b), (d), and optionally (e), which in each case independently of one another comprise at least one binder (c1), at least one organic solvent (c2), and at least one pigment (c3),
(d) a plurality of different, binder-free dye solutions, which each independently of one another comprise at least one organic solvent (d1) and at least one dye (d2), and
(e) optionally one or more different organic solvents, which may optionally comprise at least one additive and/or at least one crosslinking agent.
US Pat. No. 10,428,211

FLUOROPOLYMER COMPOSITION FOR MOBILE ELECTRONIC DEVICE

SOLVAY SPECIALTY POLYMERS...

1. A fluoropolymer composition (C), said composition (C) comprising:at least one vinylidene fluoride (VDF) homopolymer [PVDF] in an amount of from 55 to 85% wt, said PVDF possessing a first molecular weight (MPVDF);
at least one VDF semi-crystalline copolymer comprising recurring units derived from VDF and recurring units derived from HFP [VDF copolymer] in an amount of from 15 to 45% wt, said VDF copolymer possessing a second molecular weight (MVDF copolymer) such that MVDF copolymer is higher than MPVDF;
the % wt being with respect to the sum of weights of PVDF and VDF copolymer, and
at least one high density ethylene polymer (PE), comprising more than 70% weight of recurring units derived from ethylene, and optionally comprising recurring units derived from at least one alpha-olefin different from ethylene, said polymer (PE) possessing a density of from 930 to 970 kg/m3, said polymer (PE) being comprised in an amount of at least 0.05 weight parts and at most 5 weight parts, per 100 weight parts of combined amount of PVDF and VDF copolymer.
US Pat. No. 10,426,164

METHODS AND COMPOSITIONS FOR CLEANING AND DISINFECTING SURFACES

Maria Beug-Deeb, inc., R...

1. A method of reducing bacteria in a biofilm on a biofilm-containing environmental surface;wherein
the environmental surface is a washable, nonporous surface;
the method comprising contacting the environmental surface with an aqueous composition comprising
an organic surfactant derived from the saponification of one or more natural oils consisting essentially of
at least 1-6% caproic, caprylic and capric acid salts, and at least 30% lauric and myristic acid salts; and
wherein the organic surfactant and citric acid are each present in sufficient amounts to achieve at least a 3 log reduction (99.9%) of bacteria on the biofilm-containing environmental surface within two minutes or less.
US Pat. No. 10,428,212

POLY(VINYL ACETAL) RESIN COMPOSITIONS, LAYERS, AND INTERLAYERS HAVING ENHANCED OPTICAL PROPERTIES

Solutia Inc., St. Louis,...

1. An interlayer comprising:a first resin layer comprising a first poly(vinyl acetal) resin and a first plasticizer;
a second resin layer adjacent to said first resin layer, wherein said second resin layer comprises a second poly(vinyl acetal) resin and a second plasticizer; and
a solid refractive index (RI) additive wherein said solid RI additive is a physical RI additive selected from polyadipates, polystyrene having a molecular weight of less than 2500, epoxides, phthalic acid esters, benzoic acid esters, and combinations thereof, or said solid RI additive is an aromatic reactive RI additive;
wherein said solid RI additive is present in at least one of said first and said second resin layers in an amount of at least 1 part per hundred parts (phr) of resin.
US Pat. No. 10,428,213

(METH)ACRYLIC RESIN COMPOSITION AND RESIN MOLDED ARTICLE

Mitsubishi Chemical Corpo...

1. A (meth)acrylic resin composition comprising a (meth)acrylic polymer (P) and a phosphorus atom-containing compound (C), whereinthe (meth)acrylic polymer (P) comprises
(1) a repeating unit derived from methyl methacrylate at 19.95% by mass or more and 84.95% by mass or less,
(2) repeating units derived from a (meth)acrylic acid ester (M), including
(2-1) a repeating unit derived from a methacrylic acid ester (M1) having an aromatic hydrocarbon group or an alicyclic hydrocarbon group having from 3 to 20 carbon atoms in a side chain at 10% by mass or more and 79.5% by mass or less and
(2-2) a repeating unit derived from an acrylic acid ester (M2) having an aromatic hydrocarbon group or an alicyclic hydrocarbon group having from 3 to 20 carbon atoms in a side chain at 0.50% by mass or more and 20% by mass or less, and
(3) a repeating unit derived from a monomer (B) having two or more vinyl groups at 0.05% by mass or more and 0.40% by mass or less;
a sum of the repeating unit derived from a methacrylic acid ester (M1) and the repeating unit derived from an acrylic acid ester (M2) is 15.0% by mass or more and 80.0% by mass or less; and
an amount of the phosphorus atom-containing compound (C) with respect to 100 parts by mass of the (meth)acrylic polymer (P) is 5.0 parts by mass or more and 35 parts by mass or less.
US Pat. No. 10,428,216

GOLF BALL INCORPORATING A MIXTURE OF A THERMOSET AND/OR THERMOPLASTIC COMPOSITION AND A PLURALITY OF CONDUCTIVE NANOSHELLED STRUCTURES

Acushnet Company, Fairha...

1. A golf ball having a CoR of at least 0.700 and a compression of at least 50 and comprising at least one layer consisting of a mixture of thermoset or thermoplastic composition and a plurality of conductive nanoshelled structures that are hexagon-shaped.
US Pat. No. 10,429,755

WHITE TONER FOR ELECTROSTATIC IMAGE DEVELOPMENT, ELECTROSTATIC IMAGE DEVELOPER, TONER CARTRIDGE, PROCESS CARTRIDGE, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD

FUJI XEROX CO., LTD., To...

1. A white toner for electrostatic image development, the toner comprising:white toner particles containing a binder resin and a white pigment,
wherein when in a circularity distribution of the white pigment determined by sectional observation of the white toner particles, the cumulative 10% circularity from the smaller side is C10, and the cumulative 50% circularity is C50, the following formula (1) and formula (2) are satisfied,
0.900?C50?1.000  Formula (1):
1.00?C50/C10?1.13.  Formula (2):
US Pat. No. 10,428,217

LIQUID POTHOLE FILLER COMPOSITION AND METHOD

1. A pothole filler system of liquid and solid components for mixing in situ and poured as a liquid into a pothole, comprising: an anionic aqueous asphalt and chloroprene emulsion liquid component in a volume ratio of from about 60:40 to about 70:30 and having a pH of from about 12 to 12.9, which is shelf stable for months; a solid component comprising crumb rubber mixed with calcined clay in a weight ratio of crumb rubber to calcined clay is from about 3:1 to about 1:1; and a catalytic quantity of a hydrous calcium sulfate activator, which may be an ingredient of the solid component or can be added at the time of in situ mixing, wherein when mixed in situ, the resulting in situ mixture remains stable through hardening, and can be poured into the pothole as a liquid mixture which hardens in 60 minutes or less and can be driven on immediately upon hardening.
US Pat. No. 10,431,804

SECONDARY BATTERY AND SECONDARY BATTERY ASSEMBLY

SANYO Electric Co., Ltd.,...

1. A secondary battery comprising:an electrode assembly including a first electrode and a second electrode;
an outer body having an opening and housing the electrode assembly;
a sealing plate sealing the opening and made of a conductive material;
a deformable member that is deformed when the pressure inside the outer body becomes equal to or higher than a predetermined value; and
a conductive second electrode connecting member electrically connected to the second electrode,
wherein the sealing plate has a first through-hole,
wherein the deformable member hermetically seals the first through-hole,
wherein the second electrode connecting member is disposed on the outer side of the deformable member,
wherein a conductive conducting member is disposed between the second electrode connecting member and the deformable member,
wherein the outer diameter of the conducting member is larger than the inner diameter of the first through-hole,
wherein when the pressure inside the outer body becomes equal to or higher than the predetermined value, the deformable member is deformed and thereby brings the conducting member into contact with the second electrode connecting member and electrically connects the first electrode and the second electrode, and
wherein an insulating member is disposed between the second electrode connecting member and the conducting member,
wherein the insulating member has a second through-hole, and
wherein the conducting member has a protruding portion that protrudes toward the second electrode connecting member into the second through-hole.
US Pat. No. 10,426,170

COMPOSITIONS AND METHODS FOR REDUCING INFESTATION OF WEEDS OR UNWANTED PLANTS WHILE MINIMIZING INJURY OR DAMAGE TO PLANTS OR CROPS

BAYER CROPSCIENCE LP, St...

1. A method for controlling, mitigating, or reducing weed infestation and/or damage in a glyphosate tolerant or resistant seed, plant, or crop, comprising treating soil, a plant, and/or a plant part with as the sole herbicides:a) a HPPD inhibitor herbicide;
b) glyphosate; and
c) fomesafen,wherein said HPPD inhibitor herbicide is selected from the group consisting of mesotrione, tembotrione, isoxaflutole, and bicyclopyrone and wherein the presence of fomesafen with said a and b increases crop yield and lowers the phytotoxicity relative to said a and b combined.
US Pat. No. 10,426,171

METHODS FOR PROPHYLAXIS OF INFECTIONS IN CROPS AND ORNAMENTALS, PREFERABLY IN VITICULTURE, AND IN WOODY PLANTS

BIOPRACT GMBH, Berlin (D...

1. A method for prophylaxis of infection by Plasmopara viticola in crops and ornamental plants, comprising spraying plants with an aqueous solution of a bacterial serine protease, characterized in that said bacterial serine protease is derived from Bacillus sp. or Nocardiopsis sp.
US Pat. No. 10,427,195

CHEMICAL OXIDATION METHOD AND COMPOUNDS

OXYTEC LLC, Newton, MA (...

1. A method of reducing the concentration of perfluoroalkyl compounds in a contaminated material, the method comprising:desorbing at least one of the perfluoroalkyl compounds from the contaminated material;
forming a soluble cyclic oligosaccharide/perfluoroalkyl complex with the at least one perfluoroalkyl compound in an aqueous phase; and
destroying the cyclic oligosaccharide/perfluoroalkyl complex in the aqueous phase, wherein a concentration of the at least one perfluoroalkyl compound in the contaminated material is reduced by greater than 50% of an original concentration, and the concentration of the at least one perfluoroalkyl compound is reduced to less than 1.0 ppm in the contaminated material, wherein the contaminated material comprises at least one of soil, sediment and rock.
US Pat. No. 10,426,172

MIXTURES OF SABADILLA ALKALOIDS AND BACILLUS THURINGIENSISAND USES THEREOF

MCLAUGHLIN GORMLEY KING C...

1. A pesticidal mixture comprising an effective amount of sabadilla alkaloids and Bacillus thuringiensis wherein Bacillus thuringiensis consists of a subspecies selected from the group consisting of Bacillus thuringiensis aizawai, Bacillus thuringiensis kurstaki and combinations thereof and wherein the ratio of sabadilla alkaloids to Bacillus thuringiensis is from about 1:1 to about 1:100.
US Pat. No. 10,428,223

PRETREATMENT HAVING IMPROVED STORAGE STABILITY AND ADHESION

SIKA TECHNOLOGY AG, Baar...

1. A composition consisting essentially of:A) at least one aminosilane which has at least one hydrolyzable group bonded to Si,
B) at least one mercaptosilane which has at least one hydrolyzable group bonded to Si,
C) at least one emulsifier selected from propionamides and amino alcohol reaction products,
wherein, if the at least one emulsifier is an amino alcohol reaction product, the amino alcohol reaction product is a reaction product of an amino alcohol and at least part of the aminosilane and/or mercaptosilane, and in the amino alcohol reaction product, at least some of the hydrolyzable groups present in the at least one aminosilane and the at least one mercaptosilane are replaced by an amino alcoholate group present in the amino alcohol,
D) hydrolysis and/or condensation products of the at least one aminosilane and the at least one mercaptosilane,
E) water,
F) at least one acid, and
G) at least one surfactant.
US Pat. No. 10,428,224

LOW GLOSS POWDER COATING

TIGER DRYLAC U.S.A. INC.,...

1. A curable powder coating composition comprising one or more cross-linkable fluoro containing organic oligomer(s) and/or polymer(s) (A), one or more crosslinker(s) (B) able to react with (A), one or more compound(s) (C) able to react with (A) and/or (B), and melamine and/or a melamine derivative; wherein the one or more crosslinker(s) is distinct from the melamine and the melamine derivative.
US Pat. No. 10,428,225

LOW REFLECTANCE POWDER COATING COMPOSITION

SWIMC LLC, Cleveland, OH...

1. A powder coating composition comprising:(a) a first hydroxyl functional acrylic powder resin having a hydroxyl value of at least about 180 and having a Tg of at least 35° C.;
(b) a second hydroxyl functional acrylic powder resin having a hydroxyl value between about 45 and about 80 and having a Tg of at least 35° C.;
(c) a blocked isocyanate crosslinker reactive with the first hydroxyl functional acrylic powder resin and the second hydroxyl functional acrylic resin; and
(d) wollastonite;and wherein the weight ratio of the first acrylic powder resin to the second acrylic powder resin is at least about 0.5, the first acrylic powder resin is present at a level to provide between about 33.3 weight percent and 85.1 weight percent of the total combined weight of the first acrylic powder resin and the second acrylic powder resin, the blocked isocyanate crosslinker is present at a level about 1.0 to about 1.5 equivalents of isocyanate functionality for each equivalent of active hydrogen of the first and second hydroxyl functional acrylic resins, the wollastonite is present at a level of at least 10% to about 25% by weight of the coating composition, and the coating composition when applied to a substrate and cured will have a 60° gloss less than 1 and an 85° gloss 3.5 or less.
US Pat. No. 10,428,226

SOL-GEL COATING COMPOSITIONS AND RELATED PROCESSES

The Boeing Company, Chic...

17. A corrosion-resistant coated product, comprising:a plurality of ultraviolet (UV)-cured sol-gel layers on a substrate, each of the UV-cured sol-gel layers comprising a photoinitiator and a polymer composite of a methacryloxyalkyl alkoxysilane, an aryl alkoxysilane, an aminoalkyl alkoxysilane, a glycidoxyalkyl alkoxysilane, a zirconium alkoxide, and an organic acid, and each of the UV-cured sol-gel layers having a ratio of a number of moles of silicon to a number of moles of zirconium (nSi/nZr) ranging from about 2 to about 10.
US Pat. No. 10,426,179

NON-LAURIC NON-TRANS FAT COMPOSITION FOR CHOCOLATE COATING

FUJI OIL COMPANY LIMITED,...

1. A fat composition for chocolate coating that contains a fat, wherein the fat satisfies all the following requirements (A) to (F) and having a rising melting point of 35° C. or higher, and the fat composition satisfies all the following requirements (a) to (d):(A) a content of C8-12 saturated fatty acids in a constituent fatty acid composition of the fat being 3 wt % or less with respect to a total weight of the fat;
(B) a content of C14-20 saturated fatty acids in the constituent fatty acid composition of the fat being 40 to 90 wt % with respect to a total weight of the fat;
(C) a content of C16-20 unsaturated fatty acids in the constituent fatty acid composition of the fat being 10 to 60 wt % with respect to a total weight of the fat;
(D) a content of C8-22 saturated fatty acids in the constituent fatty acid composition of the fat being 48.6 to 69.1 wt % with respect to the total weight of the fat;
(E) a content of C16 saturated fatty acids and C18 saturated fatty acids in the constituent fatty acid composition of the fat being 90 parts by weight or more relative to a total of 100 parts by weight of C8-22 saturated fatty acids; and
(F) a content of trans fatty acids in the constituent fatty acid composition of the fat being 3 wt % or less with respect to the total weight of the fat,
(a) an SSS content of 6 to 15 wt % with respect to a total weight of the fat composition;
(b) an S2U content of 10 to 45 wt % with respect to the total weight of the fat composition;
(c) an SU2+UUU content of 40 to 70 wt % with respect to the total weight of the fat composition, wherein 5 wt % or more of UUU is OOO with respect to the total weight of the fat composition; and
(d) a PPP+P2St content of 70 parts by weight or more relative to 100 parts by weight of SSS,
wherein S represents a C16 or higher saturated fatty acid, U represents a C16 or higher unsaturated fatty acid, SSS represents a triglyceride in which three molecules of S are bound, S2U represents a triglyceride in which two molecules of S and one molecule of U are bound, SU2 represents a triglyceride in which one molecule of S and two molecules of U are bound, UUU represents a triglyceride in which three molecules of U are bound, P represents palmitic acid, St represents stearic acid, O represents oleic acid, PPP represents a triglyceride in which three molecules of P are bound, P2St represents a triglyceride in which two molecules of P and one molecule of St are bound, and OOO represents a triglyceride in which three molecules of O are bound,
wherein the fat having a rising melting point of 35° C. or higher comprises one kind or two kinds of randomly transesterified fats and a content of the randomly transesterified fat is 60 wt % or more.
US Pat. No. 10,427,971

ULTRAVIOLET-ABSORBING GLASS ARTICLE

AGC Inc., Chiyoda-ku (JP...

1. An ultraviolet absorbing glass article comprising, in terms of % by mass based on oxides:SiO2 66 to 75%,
Na2O 10 to 20%,
CaO 5 to 15%,
MgO 0 to 6%,
Al2O3 0 to 5%,
K2O 0 to 5%,
total iron (t-Fe2O3) as represented by Fe2O3 0.8% or more and less than 2.4%,
Cr2O3 0 to 0.01%,
CoO 0.02 to 0.04%,
Se 0.0005 to 0.0045%, and
TiO2 more than 0% and 1% or less,
a Redox, which is (an content of divalent iron (Fe2+) in terms of Fe2O3)/(a total content of divalent iron (Fe2+) in terms of Fe2O3 and trivalent iron (Fe2+) in terms of Fe2O3), being 20% or more and 30% or less,
the Redox, and the contents of t-Fe2O3 and TiO2 satisfying expression (1),
the contents of t-Fe2O3, Cr2O3, CoO, and Se satisfying expression (2),
the ultraviolet absorbing glass article having:
an ultraviolet transmittance (TUV) (ISO 9050:2003) at a sheet thickness of 3.5 mm being 2% or less,
a visible light transmittance (TVA) (JIS R 3106 (1998)) measured by using a standard illuminant A at a sheet thickness of 3.5 mm being 12% or more and 25% or less,
a solar radiation transmittance (TE) (JIS R 3106 (1998)) at a sheet thickness of 3.5 mm being 22% or less, and
an excitation purity (Pe) measured by using a standard illuminant C at a sheet thickness of 3.5 mm being 10% or less:
1.77×(1?Redox/100)×(t-Fe2O3)+0.48×(TiO2)?1.73  (1), and
5.0?(t-Fe2O3)+10×(Cr2O3)+90×(CoO)+1100×(Se)?8  (2).
US Pat. No. 10,427,972

TRANSPARENT SILICATE GLASSES WITH HIGH FRACTURE TOUGHNESS

CORNING INCORPORATED, Co...

1. A glass based article comprising:SiO2 in the range of 35 mol % to 80 mol %;
Al2O3 in the range of 1 mol % to 15 mol %;
alkali metals in the range of 0 mol % to 5 mol % of total alkali metals, collectively; and
two or more metal oxides selected from the group consisting of La2O3, BaO, Ta2O5, Y2O3, and HfO2, wherein the combined molar percentages of the two or more metal oxides are at least 15 mol %, and
wherein the glass based article has a fracture toughness of at least 0.86 MPa*m0.5.
US Pat. No. 10,428,228

PRE-TREATMENT AND CLEANING OF EQUIPMENT USED WITH UNCURED CEMENTITIOUS MATERIALS

Arris Technologies, LLC, ...

1. A system for treating equipment for mixing, placing or finishing a cementitious material, comprising:a composition comprising a colloidal silica, the composition formulated to enable the colloidal silica to prevent cementitious material from adhering to a surface of the equipment and/or to enable the colloidal silica to soften hardened and/or cured cementitious material to facilitate removal of the hardened and/or cured cementitious material from the surface of the equipment; and
abrasive particles capable of use with the composition.
US Pat. No. 10,426,181

METHOD FOR PREPARING HIGH ACID RTD WHOLE GRAIN BEVERAGES

The Quaker Oats Company, ...

1. A method for preparing a low viscosity whole grain flour slurry comprising the following steps to be performed in the order listed:a) dispersing whole grain flour in water at a ratio of 1:8 to 1:20 at a temperature of 87 to 99° C. to obtain a flour-water mixture;
b) reducing the temperature of the flour-water mixture to 49-71° C.;
c) adding alpha-amylase to reduce the viscosity of the flour-water mixture to 40 to 60 cp when measured at about 70° C., wherein alpha-amylase is the only enzyme added to the mixture; and
d) acidifying the flour-water mixture to reduce the pH of the flour-water mixture to less than 5 and to obtain a low viscosity whole grain flour slurry wherein about 50 percent of the flour contained in the slurry has an average particle size of less than 91 microns.
US Pat. No. 10,427,973

PYROLYTIC HYBRID ENAMEL

Ferro Corporation, Mayfi...

1. A composition for forming an enamel cover coat, the composition comprising at least a first glass frit comprising by weight:from about 6.3% to about 7.4% Na2O;
from about 6.3% to about 7.4% K2O;
from about 9.9% to about 11.9% SiO2;
from about 25.7% to about 29.7% P2O5;
from about 12.7% to about 14.7% ZrO2;
from about 16.8% to about 20.8% Al2O3;
from about 0.6% to about 4.0% TiO2;
from about 0.1% to about 2.0% Li2O;
from about 0.1% to about 2.0% BaO;
from about 0.1% to about 5.0% Co2O3;
from about 0.1% to about 1.0% Cr2O3;
from about 10.3% to about 14.3% B2O3; and
from about 0.1% to about 3.0% F.
US Pat. No. 10,426,182

METHOD FOR PRESERVING FOOD

NECST S.R.L., Padua (IT)...

1. A method for preserving organoleptic characteristics associated with a cooked food, comprising the steps of:placing the cooked food having organoleptic characteristics of: taste, odor, appearance and texture in an atmospheric preservation chamber;
establishing and maintaining a temperature in the atmospheric preservation chamber in a range between 58° C. to 72° C.;
introducing a non-oxidizing gas into the atmospheric preserving chamber;
establishing and maintaining an oxygen pressure in the atmospheric preserving chamber below 10 kPa; and,
maintaining the temperature, pressure, and organoleptic characteristics of: taste, odor, appearance and texture until the cooked food product is removed from the preserving chamber no sooner than 24 hours from the time the cooked food is placed in the atmospheric preserving chamber.
US Pat. No. 10,426,950

METHODS AND DEVICES FOR TREATING PARASYMPATHETIC BIAS MEDIATED CONDITIONS

Palo Alto Investors, Pal...

1. A method of treating a subject, the method comprising:testing a subject that has not been previously diagnosed with a food allergy and has ingested a nutritional composition known to have a high incidence of allergic reaction to determine that the subject has parasympathetic bias and vagal bias by measuring one or more aspects of the subject's autonomic nervous system selected from the group consisting of: an amount of T helper cells, a conduction, a catecholamine level, heart rate variability, a hormone level, a chronotropic vasodilator response and an inotropic vasodilator response, to detect the parasympathetic bias and vagal bias; and
modulating at least a portion of the tested subject's autonomic nervous system via an electrical protocol comprising applying an electrical stimulation to at least one nerve fiber of the subject via a device to increase the sympathetic/parasympathetic activity ratio in a manner effective to treat the subject for the food allergy.
US Pat. No. 10,428,230

SYNERGISTIC MIXED SOLVENTS-BASED COMPOSITIONS WITH IMPROVED EFFICIENCY OF PERFORMANCE AND ENVIRONMENTAL SAFETY FOR REMOVAL OF PAINT, VARNISH AND STAIN

1. A non-aqueous composition for removing a paint or varnish coating from wood, metal or concrete surfaces which consists essentially of a mixture of environmentally acceptable mixed polar solvents consisting essentially of a first environmentally acceptable polar solvent selected from the group consisting of an ester amide, a lactone, an organic carbonate, a dialkyl sulfoxide, an alkyl imidazolidinone, an arylalkyl alcohol, and mixtures thereof, and a second environmentally acceptable polar solvent selected from the group consisting of an ester amide, a lactone, an organic carbonate, a dialkyl sulfoxide, an alkyl imidazolidinone, an arylalkyl alcohol, and mixtures thereof, wherein each of the first and second solvents have a Hansen's fractional polar solubility parameter component of greater than about 0.16 or 16% and at least one of the first or second solvents has a Hansen's fractional polar solubility parameter component of greater than about 0.25 or 25%; an activator; and optionally one or more additional environmentally acceptable polar solvents and optionally one or more additives chosen from rheology modifiers, bittering agents, fragrance, diluents, and/or emulsifiers, wherein the relative amounts of the first and second solvents are sufficient to cause an increase in the removal of coating of at least 5 percent compared to a composition containing either of the first or second solvents alone, and wherein the composition is devoid of N-methyl pyrrolidone.
US Pat. No. 10,431,817

ELECTRODE MATERIAL FOR LITHIUM-ION SECONDARY BATTERY AND METHOD FOR MANUFACTURING THE SAME, ELECTRODE FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY

SUMITOMO OSAKA CEMENT CO....

1. An electrode material for a lithium-ion secondary battery comprising:an inorganic particle represented by General Formula LiFexMn1-x-yMyPO4 (0.02?x?1.0, 0?y·0.14, here, M represents at least one element selected from Mg, Ca, Co, Sr, Ba, Ti, Zn, B, Al, Ga, In, Si, Ge, and rare earth elements); and
a carbonaceous film that coats a surface of the inorganic particle,
wherein an amount of carbon is 0.8% by mass or more and 2.5% by mass or less, and
the carbonaceous film having a volume of micropores in a micropore diameter range of 2 nm or more and 200 nm or less is 3×10?2 cm3/g or more and 3×10?1 cm3/g or less.
US Pat. No. 10,428,231

GEL PARTICLES, INK COMPOSITION AND PRODUCTION METHOD THEREOF, PHOTOSENSITIVE COMPOSITION, AND IMAGE FORMING METHOD

FUJIFILM CORPORATION, To...

1. An ink composition for ink jet comprising:gel particles which have a polymerizable group, and a three-dimensional crosslinked structure including at least one bond selected from a urethane bond and a urea bond, and enclose a photopolymerization initiator; and
water.
US Pat. No. 10,431,818

ACTIVE LITHIUM RESERVOIR FOR LITHIUM-ION BATTERIES

Albemarle Germany GmbH, ...

1. A method for providing an active lithium reservoir for lithium batteries from at least one hydrogen-containing lithium-donating additive selected from the group of lithium hydride, lithium amide, lithium imide and tetra-lithium ammonium hydride, which method comprisesin an electrochemical cell, electrically contacting the lithium-donating additive and a voltage which is at least equal to the standard oxidation potential of the lithium-donating additive; or
outside an electrochemical cell, contacting the lithium-donating additive and an electrode material having a higher standard oxidation potential than the lithium-donating additive;
causing the lithium-donating additive to decompose to release lithium.
US Pat. No. 10,426,184

SEAWEED MEAL AND METHOD OF MAKING THE SAME

NUTRIOMIX, INC., Pasaden...

1. A method of preparing a high quality seaweed meal suitable for food applications, consisting of:cleaning seaweed material with water, wherein the seaweed material is dry, fresh, or rehydrated seaweed material;
pre-treating the seaweed with an alkali;
pre-treating the seaweed with an acid; and
treating the pre-treated seaweed with a cellulase, thereby to obtain the seaweed meal.
US Pat. No. 10,428,233

WATER-BASED INK SET FOR INK-JET PRINTING

Brother Kogyo Kabushiki K...

1. A water-based ink set for ink-jet recording, wherein the water-based ink set comprises:a water-based yellow ink containing a yellow pigment, a resin dispersant, and water;
a water-based magenta ink containing a magenta pigment, a resin dispersant, and water;
a water-based cyan ink containing a cyan pigment, a resin dispersant, and water;
a water-based black ink containing self-dispersible carbon black and water,
wherein the self-dispersible carbon black has an average particle size of 120 to 170 nm, and
the water-based color ink selected from the group consisting of the water-based yellow ink, the water-based magenta ink, and the water-based cyan ink which contains a color pigment of which average particle size is largest among the yellow pigment, the magenta pigment, and the cyan pigment, further contains a dye, and the remaining two water-based color inks contain no dye.
US Pat. No. 10,427,978

COATED BUILDING PANELS AND ARTICLES CONTAINING CALCIUM SULFATE HEMIHYDRATE

UNITED STATES GYPSUM COMP...

1. A coated interior panel comprising:a building panel comprising one of the group consisting of gypsum panels, cement panels, panels having both gypsum and cement and mixtures thereof; and
a primer coating on the panel surface obtained by applying to the panel surface a coating having a thickness of about 5 to about 20 mil when said coating is wet, said coating comprising:
10-40% by weight of a latex emulsion binder having a molecular weight greater than 10,000 Daltons;
30-80% by weight calcium sulfate hemihydrate;
less than 8% by weight of a dual set inhibiting agent, wherein the dual set inhibiting agent consists of a first set inhibiting agent and a second set inhibiting agent, and wherein
the first set inhibiting agent is a compound of 0.1% or more by weight selected from the group consisting of tetrasodium pyrophosphate, tetrapotassium pyrophosphate, aminotri(methylene-phosphonic acid), diethylenetriamine penta (methylene phosphonic acid) trisodium salt, hexamethylene diamine tetra(methylene phosphonic acid) and mixtures thereof; and
the second set inhibiting agent is a polymer of 0.05% or more by weight and having a molecular weight from 2,000 Daltons to 6,000 Daltons and selected from the group consisting of a polymer made from a monomer selected from the group consisting of vinyl acrylates, vinyl acetates, vinyl chlorides, ethylenes, styrenes, substituted styrenes and mixtures thereof; and
10-40% by weight water; and
wherein said coating does not comprise a set accelerator.
US Pat. No. 10,427,212

COMPOSITIONS AND METHODS FOR MODIFIED ESTER-CURATIVES AND REDUCTION OF FORMALDEHYDE EMISSION AND ODOR IN ESTER-CURED PHENOLIC BINDER SYSTEMS

HA-International, LLC, W...

1. A method for reducing formaldehyde emissions from ester-cured foundry binders used in the formation of foundry molds and cores, the method comprising the steps of:(a) combining an aggregate with a water soluble alkaline phenolic resole resin to form a first admixture;
(b) combining an ester-curative with resorcinol to form a modified ester-curative; and
(c) combining the first admixture with the modified ester-curative to form a second admixture;
wherein the modified ester-curative is configured to affect a reduced emission of formaldehyde from the second admixture.
US Pat. No. 10,428,236

POLYURETHANE UREA RESIN COMPOSITION EXHIBITING UV-ABSORPTION-AGENT RESISTANCE, MOULDED BODY USING SAID COMPOSITION, AND COATING MATERIAL

TOSOH CORPORATION, Shuna...

1. A polyurethane urea resin composition having UV-absorption-agent resistance, comprising:an organic solvent; and
a polyurethane urea resin dissolved in the organic solvent and comprising a monomer unit derived from a polyol, a monomer unit derived from a polyisocyanate, a monomer unit derived from a molecular weight modifier, and a monomer unit derived from a diamine, and the polyurethane urea resin has a urea group concentration in a range of 0.5 to 1 mmol/g, a urethane group concentration of 1 mmol/g or less, and a urethane group concentration ratio in a range of 40 to 59% where the urethane group concentration ratio=the urethane group concentration×100/(the urethane group concentration+the urea group concentration).
US Pat. No. 10,428,237

AQUEOUS COATING COMPOSITION WITH SOFT TOUCH UPON DRYING

DSM IP ASSETS B.V., Heer...

1. An aqueous coating composition comprising dispersed polymer particles,wherein
(i) the dispersed polymer particles are polyurethane-vinyl polymer hybrid particles obtained by free-radical polymerization of at least one vinyl monomer in the presence of a polyurethane,
(ii) the polyurethane and the vinyl polymer in the hybrid particles are present in a weight ratio of polyurethane to vinyl polymer from 1:1 to 20:1,
(iii) the polyurethane is the reaction product of at least the following components:
(a) from 5 to 40 wt. % of at least one organic difunctional isocyanate,
(b) from 0.5 to 4 wt. % of an isocyanate-reactive compound containing ionic or potentially ionic water-dispersing groups having a molecular weight of from 100 to 500 g/mol,
(c) from 40 to 80 wt. % of at least one diol having a molecular weight from 500 to 5000,
(d) from 0 to 10 wt. % of at least one active-hydrogen chain extending compound other than water with a functionality of at least 2, and
(e) from 0 to 10 wt. % of at least one diol having a molecular weight below 500 g/mol, wherein
the amounts of components (a), (b), (c), (d) and (e) are relative to the total amount of components used to prepare the polyurethane from which the building blocks from the polyurethane are emanated, and wherein
the isocyanate and hydroxy groups on the components used to prepare the polyurethane are present in a respective mole ratio (NCO to OH) in the range of from 0.8:1 to 5:1.
US Pat. No. 10,426,446

STRAW FOR THE PRESERVATION OF A PREDETERMINED DOSE OF LIQUID-BASED SUBSTANCE, IN PARTICULAR PURE OR DILUTED ANIMAL SEMEN; AND SET COMPRISING IT

IMV TECHNOLOGIES, Saint ...

1. A set comprising:a straw for the preservation of a predetermined dose of liquid-based substance, comprising a tube, a gas-permeable liquid-tight stopper, which stopper is disposed in the tube in the neighborhood of one end, which tube and which stopper are configured for the stopper to be able to slide in the tube towards another end, and an indicator component configured to emit, at least when the straw is in the filled state, light of which the spectrum comprises at least one peak each having a respective crest of predetermined wavelength; and
a detector for recognition of said straw, wherein said detector is configured for detecting absence or presence of said at least one peak in the light spectrum emitted by said indicator component;
said detector being part of a straw filler comprising a processor connected to said detector and configured to emit a stop signal for said straw filler in case said detector detects a straw in which there is absence of said at least one peak in said spectrum of the light emitted by said indicator component.
US Pat. No. 10,427,215

PUNCH UNIT AND POWDER PRESS MOLDING DEVICE FOR MANUFACTURING COMPACTED POWDER PELLET

DENSO CORPORATION, Kariy...

1. A punch unit used in a powder press molding device that includes a die plate including a cavity in which a compacted powder pellet can be formed, the powder press molding device including a ram moving in a direction approaching the die plate and in a direction away from the die plate, the punch unit comprising:a punch inserted into the cavity of the die plate when the ram approaches the die plate; and
a supporting portion supporting the punch reciprocatably in a moving direction of the ram, the punch unit being movable along a plane intersecting with the moving direction of the ram in a state where the punch is removed from the cavity.
US Pat. No. 10,427,986

ANTIMICROBIAL GLAZE AND PORCELAIN ENAMEL VIA DOUBLE LAYER GLAZE WITH HIGH ZINC CONTENT

Ideal Standard Internatio...

1. A multilayer antimicrobial glaze/enamel, comprising:a base glaze layer, wherein the base glaze layer comprises less than about 8.0 percent by weight ZnO; and
a top glaze layer, wherein the top glaze layer comprises about 8.0 percent by weight to about 35.0 percent by weight ZnO,
wherein the base glaze layer is between about 300 ?m and 1000 ?m in thickness;
wherein the top glaze layer is between about 25 ?m and 250 ?m in thickness;
wherein relative thicknesses and concentrations of the top glaze layer and base glaze layer are such that a total concentration of the multilayer antimicrobial glaze/enamel is less than about 5.0 percent by weight ZnO; and
wherein the multilayer antimicrobial glaze/enamel is substantially free of surface defects.
US Pat. No. 10,427,987

ORGANIC FERTILIZER FOR VEGETABLES AND ITS PREPARATION METHOD

1. A method of preparation of an organic fertilizer for vegetables comprising:picking mature okra fruits then washing and sterilizing the okra fruits;
anaerobic depositing of the sterilized okra fruits for 3 to 5 days at a temperature range of 18 to 25 degree C. to obtain a matrix of the organic fertilizer for vegetables;
adding 1 part of a colloidal fluid of Bacillus to 0.95 to 0.98 part of the matrix of the organic fertilizer for vegetables to obtain a second fluid of the organic fertilizer for vegetables by an anaerobic fermentation for 30-60 days under hermetic closure, shading and sterilization at temperature 20 to 35 degree C.; and
adding 5 to 10 fractions of the second fluid of the organic fertilizer for vegetables to a mixture of 10 to 15 fractions of chicken droppings, 20 to 25 fractions of soybean crop waste, 10 to 15 fractions of plant ashes and 45 to 60 fractions of water followed by standing for 30 to 60 days at temperature of 20 to 35 degree C. to obtain the organic fertilizer for vegetables.
US Pat. No. 10,427,989

ANTI-FUNGAL SEED TREATMENT FORMULATIONS, TREATED SEEDS, AND METHODS

Germain Seed Technology, ...

1. A coated seed comprising:a seed and
a coating at least partially surrounding the seed,
wherein the coating comprises a fungicide, a micronutrient metal, and a chelating agent, the fungicide comprising copper (II) hydroxide, wherein the amount of copper (II) hydroxide is from about 0.12 mg/ seed to about 0.21 mg/ seed.
US Pat. No. 10,428,246

ADHESIVE COMPOSITION

INDUSTRIAL TECHNOLOGY RES...

1. An adhesive composition, comprising:3-10 parts by weight of polyvinylidene fluoride (PVDF), wherein the polyvinylidene fluoride comprises two polyvinylidene fluorides with different weight average molecular weights ranging from 20000 to 3000000, and at least one of the polyvinylidene fluorides has a carboxyl group;
0.1-0.5 parts by weight of polyvinyl butyral (PVB); and
0.1-3 parts by weight of a conductive powder.
US Pat. No. 10,427,992

ETHANE OXIDATIVE DEHYDROGENATION AND ACETIC ACID RECOVERY

SHELL OIL COMPANY, Houst...

1. A process for oxidative dehydrogenation of ethane, comprising the steps of:(a) feeding a gas stream comprising ethane and propane to a distillation column to obtain a stream comprising propane and a stream comprising ethane;
(b) feeding at least a part of the gas stream comprising ethane obtained in step (a) to a reactor;
(c) contacting, in the reactor, oxygen and ethane and optionally ethylene with a catalyst comprising a mixed metal oxide;
(d) cooling the reactor effluent and, simultaneously and/or in a subsequent step, add water to the reactor effluent to obtain a liquid stream comprising water and acetic acid and a gas stream comprising ethylene;
(e) recovering the acetic acid from the liquid stream obtained in step (d) by means of solvent extraction;
wherein at least 50 wt % of the mixed metal oxide in the catalyst used in step (c) is in the orthorhombic M1 crystalline phase; and
wherein the mixed metal oxide in the catalyst used in step (c) comprises:
molybdenum, vanadium and antimony, or
molybdenum, vanadium, niobium and optionally tellurium or antimony.
US Pat. No. 10,428,248

COMPOSITIONS, MATERIALS, AND METHODS FOR ENHANCING 3D PRINTER PLATFORM ADHESION AND/OR REDUCING WARPAGE IN PRINTED PARTS

1. A composition for promoting adhesion between a 3D printed material and a print platform comprising:0. 05-7 wt. % urea;
1-15 wt. % gelatin;
1-8 wt. % acetic acid;
58-99 wt. % water; and
0.1-5 wt. % polyvinylpyrrolidone, wherein the weight percentage is with respect to the total weight of the composition.
US Pat. No. 10,426,714

SPRAYABLE SUNSCREEN COSMETIC

SHISEIDO COMPANY, LTD., ...

1. A water-in-oil emulsified sunscreen cosmetic, comprising:(A) 6 to 40 mass % of an ultraviolet ray absorbing agent;
(B) an organically modified clay mineral;
(C) an oil phase thickener selected from the group consisting of dextrin fatty acid esters, sucrose fatty acid esters, and fatty acids solid at ambient temperature and salts thereof;
(D) a silicone-based surfactant having an HLB of less than 8;
(E) a spherical resin powder;
(F) a volatile silicone oil; and
(G) one or more non-volatile liquid oils other than silicone oils;
wherein a ratio of [total amount of ingredient (B)+ingredient (C)]/[a total amount of (G) non-volatile liquid oils other than silicone oils] is at least 0.04 and less than 0.68.
US Pat. No. 10,427,994

SEPARATION PROCESS FOR C8 AROMATICS MIXTURE

SCG CHEMICALS CO., LTD., ...

1. A process for the distillative separation of ethylbenzene from a mixture comprising ethylbenzene and at least one other C8 aromatic compound, the process comprising:adding at least one solvent to a distillation column, the at least one solvent including one or more of chloroform, carbon tetrachloride, dimethylamine, diethylamine, acetonitrile, acetaldehyde, 1-propanal, methyl isopropyl ketone, 3-methyl-2-pentanone, 3,3-dimethyl-2-butanone, 2-pentanone, 2-methylpropanal, 1-butanal, cyclopentanone, acetone, or ethanol;
adding one or more of water or steam to the distillation column; and
distilling said mixture in the distillation column in the presence of an extractive solvent, the at least one solvent, the one or more of water or steam, and at a sub-atmospheric pressure.
US Pat. No. 10,428,250

METHOD FOR PRODUCING TEXTILE PRODUCTS, PRODUCTS OBTAINABLE THEREFROM AND METHOD TO RECLAIM THE PRODUCTS

DSM IP ASSETS B.V, Heerl...

1. A hot melt adhesive comprising a polymer P in an amount of at least 50% by weight of the hot melt adhesive composition, whereinthe polymer P is a polyester which is a condensation polymerization reaction product of a dicarboxylic acid and a polyol having two hydroxyl groups per molecule, and wherein
the polymer P is semi-crystalline and has a melting point from 75 to 150° C., a glass transition temperature below 40° C. and a melt viscosity at 150° C. of lower than 100 Pa·s and higher than 8 Pa·s, wherein
the hot melt adhesive is thermoplastic.
US Pat. No. 10,431,325

METHODS TO IDENTIFY AMINO ACID RESIDUES INVOLVED IN MACROMOLECULAR BINDING AND USES THEREFOR

NOVARTIS AG, Basel (CH) ...

1. An in vitro method of producing a protein variant which exhibits increased binding to a macromolecule, the method comprisingreplacing or deleting one or more hot-spot amino acid residues in the protein by site-directed mutagenesis, wherein binding affinity of the modified protein to a macromolecule is increased, as compared to a corresponding protein lacking the replacement or deletion of one or more hot-spot amino acid residues,
(i) wherein the one or more hot-spot amino acid residues were identified using a computer-implemented method for predicting hot-spot amino acid residues of the protein, or portion thereof,
wherein the protein, or portion thereof, was represented in a structural model comprising a plurality of amino acid residues, and wherein
(i) a cluster of highly hydrophobic amino acid residues was selected from the plurality of amino acid residues of the model, wherein the cluster comprised two or more amino acid residues each having an effective-hydrophobicity greater than a chosen threshold, and wherein each amino acid residue in the cluster was within a first defined distance of at least one other amino acid residue in the cluster;
(ii) one or more solvent-exposed polar amino acid residues within a second defined distance of at least one amino acid residue in the cluster of highly hydrophobic amino acid residues was selected from the plurality of amino acid residues of the model;
(iii) amino acid residues that did not meet a criterion for evolutionary conservation were removed from the cluster of highly hydrophobic amino acid residues and from the one or more solvent-exposed polar amino acid residues, to produce a set of one or more predicted hot-spot amino acid residues; and
(iv) the one or more predicted hot-spot amino acid residues were stored;
wherein, if the hot-spot amino acid residue is replaced and is in the cluster of highly hydrophobic amino acid residues, it is replaced with an amino acid residue which is more hydrophobic such that the binding affinity is increases, or if the hot-spot amino acid residue is replaced and is from the one or more solvent-exposed polar amino acid residues, it is replaced with an amino acid residue which is more hydrophilic such that the binding affinity is increases.
US Pat. No. 10,426,715

LIPOSOME COMPOSITION

KOSE CORPORATION, Tokyo ...

1. A liposome comprising the following ingredients (a) to (e):(a) A phospholipid
(b) A Tremella fuciformis extract
(c) Vitamin E or a derivative thereof
(d) A polyhydric alcohol having an IOB value of 1.5 to 5
(e) Water,
wherein the ingredient (d) consists of one or more selected from the group consisting of 1,3-butylene glycol, glycerin, and dipropylene glycol, and
wherein content of the ingredient (d) contained in the liposome is in the range of 10 to 25%.
US Pat. No. 10,427,995

MOLECULAR SIEVES MEDIATED UNSATURATED HYDROCARBON SEPARATION AND RELATED COMPOSITIONS, MATERIALS, METHODS AND SYSTEMS

CALIFORNIA INSTITUTE OF T...

1. A sieved hydrocarbon mixture obtained by separating an eight-membered monocyclic unsaturated hydrocarbon from a hydrocarbon mixture further comprising additional nonlinear unsaturated C8H2m hydrocarbons with 4?m?8,wherein separating the eight-membered monocyclic unsaturated hydrocarbon comprises
providing a 10-ring pore molecular sieve having a sieving channel with a 10-ring sieving aperture with a minimum crystallographic free diameter greater than 3 ? and a ratio of the maximum crystallographic free diameter to the minimum crystallographic free diameter between 1 and 2,
the 10-ring pore molecular sieve having a T1/T2 ratio?20:1 wherein T1 is an element independently selected from Si and Ge or a combination thereof, and T2 is an element independently selected from Al, B and Ga or a combination thereof,
the 10-ring pore molecular sieve further having a counterion selected from NH4+, Li+, Na+, K+ and Ca++ or a combination thereof, and
contacting the hydrocarbon mixture with the 10-ring pore molecular sieve at a temperature of ?20° C. to 60° C. for a time and under conditions to obtain a sieved hydrocarbon mixture comprising the eight-membered monocyclic unsaturated hydrocarbon at a separation concentration Cs>Ci,
wherein the 10-ring pore molecular sieve has a framework type selected from group consisting of MEL, TUN, IMF, MFI, OBW, MFS and TER, and
wherein, the sieved hydrocarbon mixture comprises the eight-membered monocyclic unsaturated hydrocarbon at a separation concentration Cs?99.3% wt.
US Pat. No. 10,428,251

TWO-PART POLYURETHANE ADHESIVES MADE USING ISOCYANATE-TERMINATED QUASI-PREPOLYMERS BASED ON POLY(BUTYLENE OXIDE)

Dow Global Technologies L...

1. A two-component polyurethane adhesive composition having a polyol component and an isocyanate component, wherein:the polyol component includes:
a) at least 35 weight percent, based on the weight of the polyol component, of one or more polyether polyols having a hydroxyl equivalent weight of 400 to 2000 and a nominal hydroxyl functionality of 2 to 4, which polyether polyols(s) are selected from homopolymers of propylene oxide and copolymers of 70 to 99% by weight propylene oxide and correspondingly 1 to 30% by weight ethylene oxide;
b) 5 to 20 parts by weight, per 100 parts by weight of ingredient a) of the polyol component, of one or more diol chain extenders;
c) 0.1 to 3 parts by weight, per 100 parts by weight of ingredient a) of the polyol component, of at least one compound having at least two primary and/or secondary aliphatic amine groups;
d) a catalytically effective amount of at least one urethane catalyst; and
e) up to 60 weight percent, based on the weight of the polyol component, of at least one particulate filler;
and the polyisocyanate component includes:
15 to 60 weight percent, based on the weight of the polyisocyanate component, of at least one isocyanate-terminated poly(butylene oxide) prepolymer having at least 2 isocyanate groups per molecule and an isocyanate equivalent weight of 700 to 3500, a poly(butylene oxide) segment having a weight of 1000 to 6000 g/mol;
20 to 50 weight percent, based on the weight of the polyisocyanate component, of at least one polyisocyanate compound having an isocyanate equivalent weight of up to 350 and 2 to 4 isocyanate groups per molecule; and
up to 50% by weight of at least one particulate filler;
wherein the isocyanate equivalent weight of the polyisocyanate component and the equivalent weight per isocyanate-reactive group of the polyol component are such that when the polyisocyanate component and the polyol component are mixed at a 1:1 ratio by volume the isocyanate index is 1.1 to 1.8.
US Pat. No. 10,431,326

METHOD FOR INDICATING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATE CANCER

PHADIA AB, Uppsala (SE)

1. A method for determining aggressive prostate cancer (PCa) markers in an individual, comprising the steps of:(i) Providing at least one biological sample from said individual;
(ii) Contacting the biological sample with an assay device comprising a first category of ligands which bind specifically to at least three kallikrein family protein PCa biomarkers, the first category of ligands including a plurality of different ligands binding specifically to each of the at least three kallikrein family protein PCa biomarkers, wherein the at least three PCa biomarkers include at least one of PSA, intact PSA (iPSA), total PSA (tPSA), free PSA (fPSA), and hK2;
(iii) Contacting the biological sample with an assay device comprising a solid phase having immobilised thereon a second category of ligands which bind specifically to at least 80 SNPs related to PCa (SNPpc), the second category of ligands including a plurality of different ligands binding specifically to each of said SNPpc, wherein
(a) said at least 80 SNPpc are selected from the group consisting of rs582598, rs439378, rs2207790, rs1046011, rs10458360, rs7525167, rs10489871, rs7529518, rs4245739, rs4512641, rs10178804, rs11900952, rs1873555, rs10191478, rs6755901, rs6545962, rs721048, rs2710647, rs12612891, rs2028900, rs1009, rs12233245, rs6760417, rs10496470, rs10199796, rs12475433, rs16860513, rs12151618, rs3765065, rs13017302, rs12988652, rs871688, rs749264, rs3771570, rs4346531, rs6770955, rs12637074, rs2660753, rs13319878, rs6437715, rs2162185, rs1515542, rs2270785, rs9830294, rs1439024, rs6762443, rs888507, rs6794467, rs12490248, rs1477886, rs4833103, rs3796547, rs17779822, rs2366711, rs16849146, rs1894292, rs12640320, rs3805284, rs12500426, rs4699312, rs17021918, rs7679673, rs2047408, rs2647262, rs12506850, rs7658048, rs2078277, rs12505546, rs13113975, rs4246742, rs2736098, rs401681, rs11134144, rs10060513, rs40485, rs2087724, rs1482679, rs16901841, rs1295683, rs2070874, rs7752029, rs2018334, rs9358913, rs1140809, rs409558, rs3096702, rs9267911, rs2025645, rs9359428, rs6569371, rs2813532, rs1933488, rs712242, rs6934898, rs9456490, rs651164, rs3120137, rs9364554, rs9457937, rs10486562, rs10807843, rs7801918, rs6962297, rs2465796, rs6957416, rs7777631, rs2272316, rs6961773, rs2132276, rs13265330, rs16887736, rs2911756, rs2272668, rs2339654, rs1380862, rs9297746, rs12543663, rs10086908, rs16901922, rs1016343, rs17832285, rs16901979, rs4871779, rs10107982, rs16902094, rs620861, rs17467139, rs6983267, rs9297756, rs10094059, rs7818556, rs1992833, rs986472, rs12552397, rs4273907, rs4237185, rs753032, rs11253002, rs2386841, rs10795841, rs10508422, rs7075945, rs10508678, rs539357, rs10826398, rs3818714, rs7090755, rs10993994, rs4382847, rs1891158, rs10887926, rs10788160, rs6579002, rs10832514, rs7358335, rs1944047, rs3019779, rs10896437, rs12793759, rs7106762, rs7102758, rs2449600, rs585197, rs2509867, rs11568818, rs7125415, rs11601037, rs11222496, rs4570588, rs6489721, rs3213764, rs17395631, rs4423250, rs11168936, rs10875943, rs3759129, rs902774, rs1827611, rs4760442, rs11610799, rs6539333, rs11067228, rs7485441, rs6489794, rs4119478, rs17070292, rs2293710, rs17256058, rs1950198, rs2331780, rs7141529, rs12880777, rs17123359, rs785437, rs524908, rs12903579, rs7178085, rs7164364, rs896615, rs11634741, rs9972541, rs12594014, rs11631109, rs1558902, rs8044335, rs2738571, rs885479, rs385894, rs684232, rs4925094, rs17138478, rs11649743, rs2107131, rs7213769, rs12946864, rs306801, rs138213197, rs1863610, rs17224342, rs9911515, rs12947919, rs966304, rs17744022, rs7234917, rs1943821, rs2227270, rs1363120, rs888663, rs1227732, rs1054564, rs4806120, rs11672691, rs758643, rs3745233, rs6509345, rs2659051, rs2735839, rs1354774, rs2691274, rs6090461, rs2297434, rs6062509, rs2315654, rs2823118, rs2838053, rs398146, rs16988279, rs2269640, rs4822763, rs132774, rs747745, rs5978944, rs6530238, rs5934705, rs5935063, rs4830488, rs17318620, rs5945619, rs5945637, rs11091768, rs2473057, rs5918762, rs4844228, rs6625760 and rs17324573; or
(b) wherein said at least 80 SNPpc are selected from the group consisting of 657del5, rs10086908, rs1016343, rs10187424, rs1041449, rs10486567, rs1054564, rs10875943, rs10896449, rs10934853, rs10993994, rs11067228, rs11135910, rs11228565, rs11568818, rs11649743, rs11650494, rs11672691, rs11704416, rs12130132, rs12409639, rs12418451, rs12500426, rs12543663, rs12621278, rs12653946, rs1270884, rs130067, rs13252298, rs13385191, rs1354774, rs1363120, rs137853007, rs138213197, rs1447295, rs1465618, rs1512268, rs1571801, rs16901979, rs16902094, rs17021918, rs17632542, rs17879961, rs1859962, rs1894292, rs1933488, rs1983891, rs2018334, rs2121875, rs2242652, rs2273669, rs2292884, rs2405942, rs2660753, rs2735839, rs2736098, rs2928679, rs3213764, rs339331, rs3771570, rs3850699, rs3863641, rs401681, rs4245739, rs4430796, rs445114, rs4643253, rs4857841, rs4962416, rs5759167, rs5919432, rs5945619, rs6062509, rs620861, rs6465657, rs6763931, rs684232, rs6869841, rs6983267, rs6983561, rs7127900, rs7210100, rs721048, rs7241993, rs7611694, rs7679673, rs7931342, rs8008270, rs8102476, rs888663, rs902774, rs9364554, rs9600079, and rs9623117;
(iv) Measuring
a. a presence or concentration of each of said PCa biomarkers binding the ligands in said first category; and
b. a presence or absence of each of said SNPpc binding the ligands in said second category;
(v) Combining measurement data of the at least three PCa biomarkers binding ligands from said first category from step (iv)a according to a first predetermined equation to form a biomarker composite value, wherein the combination according to the first predetermined equation allows omission of measurement data of a subset of said PCa biomarkers when forming said biomarker composite value, wherein the subset comprises at least one, but not all, of said three kallikrein family protein PCa biomarkers;
(vi) Combining measurement data of the at least 80 SNPpc binding ligands from said second category from step (iv)b according to a second predetermined equation to form a SNPpc composite value, wherein the combination according to the second predetermined equation allows omission of measurement data of a subset of at least 10%, and up to 30%, of the SNPpc when forming the SNPpc composite value; and
(vii) Combining the biomarker composite value and the SNPpc composite value according to a third predetermined equation to form an overall composite value.
US Pat. No. 10,426,716

COMPOSITIONS AND METHODS FOR IMPROVING COLOR DEPOSIT AND DURABILITY OF COLOR IN ARTIFICIALLY COLORED HAIR

1. A hair coloring composition comprising, in a cosmetically acceptable solvent:(a) above 0 wt. % to about 50 wt. % of one or more divalent metal salts of an inorganic acid chosen from salts of calcium, zinc, iron, nickel, copper, silver, magnesium, strontium, barium, manganese, cobalt, and mixtures thereof;
(b) above 0 wt. % to about 50 wt. % of one or more monovalent or divalent metal salts of an organic acid, wherein
the one or more divalent metal salts of an organic acid are chosen from salts of calcium, zinc, iron, nickel, copper, silver, magnesium, strontium, barium, manganese, cobalt, and mixtures thereof,
the one or more monovalent metal salts of an organic acid are chosen from salts of lithium, sodium, potassium, copper, silver, and mixtures thereof, and
the organic acid of the one or more monovalent or divalent metal salts of an organic acid is chosen from C1 to C9 monocarboxylic or di-carboxylic acids, polycarboxylic acids, hydroxy-carboxylic acids, and fatty acids having at least 10 carbon atoms; and
(c) one or more colorants chosen from oxidative dye precursors, direct dyes, pigments, and mixtures thereof.
US Pat. No. 10,427,996

FERMENTATION HYDROCARBON GAS PRODUCTS SEPARATION VIA MEMBRANE

Braskem S.A., Camacari (...

1. A method of separating and purifying a fermentation product directly from a fermenter off-gas containing the fermentation product, volatile impurities and bio-byproduct impurities, comprising the steps of: (a) compressing the fermenter off-gas to produce a compressed off-gas on a multi-stage compressor system wherein the bio-byproduct impurities and water are removed, and feeding the compressed off-gas into at least one membrane module comprising a membrane, and (b) selectively permeating the volatile impurities through the membrane, resulting in a retentate stream rich in the fermentation product.
US Pat. No. 10,428,252

TWO-COMPONENT COMPOSITION

SIKA TECHNOLOGY AG, Baar...

1. A composition comprising a first component and a second component, comprisingat least one silane group-containing polymer, liquid at room temperature,
at least one liquid epoxy resin,
at least one polyetheramine, and
at least one amino- or mercaptosilane,
the polyetheramine and the amino- or mercaptosilane not being present in the same component as the liquid epoxy resin, and
90% or more of groups reactive with an epoxide group are from the at least one polyetheramine and the at least one amino- or mercaptosilane.
US Pat. No. 10,428,254

BIO-ADHESIVES

CAMBOND LIMITED, Cambrid...

1. A Distiller's Grain (DG) bio-adhesive comprising20 to 50% by weight solid content, and
50 to 80% by weight liquid content,in which the solid content comprises:50 to 89% by weight of DG mass;
1 to 20% by weight of a crosslinking agent; and
10 to 30% by weight of inorganic filler;
and in which the liquid content comprises:
0.01 to 5% by weight of a defoaming agent; and
water.
US Pat. No. 10,426,719

ORAL CARE COMPOSITIONS AND METHODS FOR WHITENING TEETH

Colgate-Palmolive Company...

1. An oral care composition, comprising:a perhydrolase enzyme that catalyzes the generation of peracetic acid between a source of hydrogen peroxide and an acyl donor, wherein the enzyme comprises an amino acid sequence comprising a CE-7 signature motif and has at least 80% amino acid sequence identity to SEQ ID NO: 1 or the enzyme comprises a CE-7 signature motif that aligns with SEQ ID NO: 2, the CE-7 signature motif comprising a) an RGQ motif at positions corresponding to positions 118-120 of SEQ ID NO: 2: b) a GXSQG (SEQ ID NO: 3) motif at positions corresponding to positions 179-183 of SEQ ID NO: 2 and an HE motif at positions corresponding to positions 298-299 of SEQ ID NO:2; and
an anhydrous matrix configured to at least partially stabilize the perhydrolase enzyme, wherein the anhydrous matrix comprises said source of hydrogen peroxide, said acyl donor, a non-aqueous anhydrous liquid, and a thickener;
wherein the non-aqueous anhydrous liquid comprises a polyethylene oxide-polypropylene oxide block copolymer;wherein the oral care composition is a single phase composition.
US Pat. No. 10,427,999

PROCESS FOR PRODUCING 2,3,3,3-TETRAFLUOROPROPENE

HONEYWELL INTERNATIONAL I...

1. A composition comprising (i) at least 50% by weight 1,1,1,2,3-pentafluoropropane (245eb), (ii) 1,1,1,2,3,3-hexafluoropropane (236ea) and (iii) 1,2,3,3,3-pentafluoropropene (1225ye), wherein the composition comprises less than 2% by weight each of 1,1,1,2,3,3-hexafluoropropane (236ea) and 1,2,3,3,3-pentafluoropropene (1225ye).
US Pat. No. 10,426,720

FILM COMPOSITIONS FOR ORAL USE

Colgate-Palmolive Company...

1. An oral care composition comprising:(i) flakes of a water dissolvable or soluble film comprising:
(a) about 15 to about 40% by weight of a water soluble cellulose polymer in the form of a polymer matrix, wherein the cellulose polymer is hydroxypropylmethyl cellulose; and
(b) a dye which is entrapped in a silica sol-gel, wherein the silica sol-gel is entrained in the polymer matrix, and
(c) betaine; and
(ii) an orally acceptable carrier vehicle,
wherein the film flakes are single-layer film flakes and are pliable;
wherein the hydroxypropylmethyl cellulose is a blend of a first hydroxypropylmethyl cellulose having a viscostity ranging from 4 to 6 mPas, and a second hydroxypropylmethyl cellulose having a viscosity ranging from 40 cps to 60 mPas; and
wherein the first and second hydroxylpropylmethyl cellulose are present in a weight ratio of about 1:1.
US Pat. No. 10,428,000

DIVIDING WALL IN ETHANOL PRODUCTION PROCESS

CARGILL, INCORPORATED, W...

1. A process for the purification of ethanol comprising the steps of:a) Distilling an aqueous feed stream comprising water, ethanol in an amount below its azeotropic concentration, and 1 to 25,000 mg/l Absolute Alcohol (AA) higher alcohols comprising propanol and/or fusel alcohols in a distillation column comprising at least one dividing wall;
b) Collecting propanol building up on a feed side of the dividing wall and feeding said propanol into the column at an outlet side of the dividing wall; and
c) Collecting a stream having a higher purity in ethanol compared to the feed stream.
US Pat. No. 10,428,001

FILM OZONOLYSIS IN A TUBULAR OR MULTITUBULAR REACTOR

P2 SCIENCE, INC., Woodbr...

1. A method of performing ozonolysis or ozone-based oxidation on a liquid or emulsified reagent using an industrial scale tubular falling film reactor with one or multiple tubes wherein the combined ozone and carrier gas flow is co-current, and wherein the ozonolysis occurs continuously without accumulation of large amounts of hazardous intermediates, and wherein the tubes are cooled by flow of a coolant; andwherein the gas flow rate is from 10 to 1500 L/min in each of said tube or tubes.
US Pat. No. 10,426,722

COMPOSITIONS CONTAINING AN ALKYLATED SILICONE ACRYLATE COPOLYMER

1. A liquid lip composition, comprising:at least one alkylated silicone acrylate copolymer in an amount of from about 20% to about 50% by weight based on a total weight of the composition;
at least one coloring agent, and
at least one non-volatile oil in an amount of from about 5% to 60% by weight based on the total weight of the composition,
wherein the composition is anhydrous and has a gloss value at 20° angle of 10 or greater.
US Pat. No. 10,426,723

COSMETIC COMPOSITIONS

Mary Kay Inc., Addison, ...

1. A method of counteracting skin irritation caused by an exfoliant, the method comprising topically applying an effective amount of a skin exfoliation composition to skin in need thereof,wherein the composition comprises:
25 wt. % to 80 wt. % water,
2 wt. % to 20 wt. % of an alpha hydroxy acid to exfoliate the skin,
0.1 wt. % to 1.5 wt. % of 4-tert-butylcyclohexanol,
0.001 wt. % to 0.1 wt. % of an aqueous extract of plankton comprising an exopolysaccharide synthesized by Vibro alginolyticus,
0.001 wt. % to 0.1% wt. % of an aqueous extract of Phragmites communis,
0.001 wt. % to 0.1 wt. % of an aqueous extract of Poria cocos, and
0.0001 wt. % to 0.01 wt. % of an aqueous extract of Cucurbita pepo (pumpkin) seed.
US Pat. No. 10,426,979

AEROSOL HAIRSPRAY PRODUCT FOR STYLING AND/OR SHAPING HAIR

The Procter and Gamble Co...

1. An aerosol hairspray product for styling and/or shaping hair wherein the product comprises:i. a container comprising a container wall which encloses a reservoir for storing a hairstyling formulation and a propellant;
ii. the hairstyling formulation comprising:
(a) from about 50% to about 99% water by total weight of the hairstyling formulation and propellant;
(b) from about 2% to about 12% of a neutralized hairstyling polymer by total weight of the hairstyling formulation and propellant, wherein the neutralized hairstyling polymer is an acrylate co-polymer;
(c) less than 0.5% of a cationic surfactant by total weight of the hairstyling formulation and propellant; and
iii. a propellant, wherein the propellant is dimethylether; and
iv. a spraying device attached to the container for dispensing the hairstyling formulation from the reservoir of the container;
wherein the hair styling formulation is free of ethanol; and
wherein the hairstyling formulation is fully dissolved.
US Pat. No. 10,428,003

METHOD FOR PRODUCING ACETIC ACID

DAICEL CORPORATION, Osak...

1. A method for producing acetic acid by reacting methanol with carbon monoxide in the presence of a catalyst system comprising a metal catalyst and methyl iodide, acetic acid, methyl acetate, and water, the method comprising:separating a process stream containing at least water, acetic acid, methyl iodide, and acetaldehyde into an aqueous phase and an organic phase, wherein an acetaldehyde concentration in a liquid to be subjected to the separation is not less than 0.026% by mass and a methyl acetate concentration in the liquid to be subjected to the separation step is 2.0 to 50% by mass, wherein
the following condition (i), the following condition (ii), the following condition (iii), and at least one of the following conditions (iv) and (v) are satisfied:
(i) an acetaldehyde concentration in the aqueous phase is not less than 0.045% by mass, and/or an acetaldehyde concentration in the organic phase is not less than 0.013% by mass;
(ii) a temperature at the time of the separation is not less than ?5° C.;
(iii) a methyl acetate concentration in the organic phase is 5.8% to 60% by mass;
(iv) an acetaldehyde distribution coefficient [{acetaldehyde concentration (% by mass) of the aqueous phase}/{acetaldehyde concentration (% by mass) of the organic phase}] is not more than 4.1; and
(v) a methyl acetate distribution coefficient [{methyl acetate concentration (% by mass) of the aqueous phase}/{methyl acetate concentration (% by mass) of the organic phase}] is not more than 0.53; and
separating and removing the acetaldehyde derived from the process stream, wherein at least a portion of the organic phase is treated.
US Pat. No. 10,426,724

ANTIHISTAMINE COMPOSITIONS, COMBINATIONS, AND USE THEREOF

APTAPHARMA INC., Pennsau...

1. An oral antihistamine combination, comprisinga first generation antihistamine in an attenuated dosage amount to provide a quick onset of action wherein a patient receiving the formulation experiences substantially no sedative effect;
a second or third generation antihistamine in a maintenance dosage amount to provide continued antihistaminic effect; and
an additional active agent, where the additional active agent is a decongestant, a cough suppressant (an antitussive), a leukotriene receptor antagonist, a 5-lipoxygenase inhibitor, a bronchodilator, an expectorant, or a combination thereof; and
a pharmaceutically acceptable excipient,
wherein at least the first generation antihistamine and the second or third generation antihistamine are formulated together into a single oral dosage form to be administered to a human patient regardless of the time of day.
US Pat. No. 10,428,004

METHOD FOR PRODUCING ACETIC ACID

DAICEL CORPORATION, Osak...

1. A method for producing acetic acid, comprising distilling a crude acetic acid solution containing acetic acid and an impurity having a higher boiling point than that of acetic acid to purify the acetic acid, wherein the method comprisescarbonylating methanol with carbon monoxide to produce acetic acid,
evaporating a reaction mixture obtained by the carbonylation to separate into a vapor stream and a residual liquid stream,
removing a lower boiling point component by distillation to separate the vapor stream into an overhead stream rich in lower boiling point component and a first acetic acid stream rich in acetic acid,
dehydrating the first acetic acid stream by distillation to separate into a second acetic acid stream more enriched with acetic acid than the first acetic acid stream, and a vapor of an overhead stream containing a larger amount of a component having a lower boiling point than that of acetic acid as compared with the second acetic acid stream, and
removing a higher boiling point component by distillation to separate the second acetic acid stream into a vapor as an overhead stream containing a larger amount of a component having a lower boiling point than that of acetic acid as compared with a bottom fraction, the bottom fraction containing a larger amount of a component having a higher boiling point than that of acetic acid as compared with the overhead stream, and a third acetic acid stream more enriched with acetic acid than the second acetic acid stream; and
wherein the distillation of the second acetic acid stream is performed under a condition involving a column bottom temperature of a distillation column of 70 to 165° C. and a column bottom pressure of the distillation column of not less than 0.01 MPaG and less than 0.255 MPaG, and
the bottom fraction of the distillation column has an acetate salt concentration of not more than 34% by mass, an acetic anhydride concentration of not more than 90% by mass, and a propionic acid concentration of not more than 90% by mass.
US Pat. No. 10,426,725

SELF-SUPPORTING FILMS FOR PHARMACEUTICAL AND FOOD USE

PHARMAFILM S.R.L., Gaggi...

1. A rapidly dissolving self-supporting and edible film, comprising:a. between 40 and 80% by weight based on the total weight of said film, of a maltodextrin,
b. between 15 and 55% by weight based on the total weight of said film, of a plasticizer, and
c. between 0.05% and 30% by weight based on the total weight of said film, of an active ingredient for food or pharmaceutical use,
wherein said film is self-supporting, is free from hydrocolloids and has a dissolution time of less than 1 minute.
US Pat. No. 10,428,005

METHOD FOR PRODUCING ACETIC ACID

DAICEL CORPORATION, Osak...

1. A method for producing acetic acid, comprising:carbonylating methanol with carbon monoxide in the presence of a catalyst system containing a metal catalyst and methyl iodide, as well as acetic acid, methyl acetate, and water in a reaction vessel to produce acetic acid;
evaporating a reaction mixture obtained by the carbonylation to separate into a vapor stream and a residual liquid stream in an evaporator;
removing a lower boiling point component to separate the vapor stream by a first distillation column into a first overhead stream rich in at least one lower boiling point component selected from methyl iodide and acetaldehyde, and a first acetic acid stream rich in acetic acid, and condensing and separating the first overhead stream to obtain an aqueous phase and an organic phase;
dehydrating the first acetic acid stream by a second distillation column to separate into a second overhead stream rich in water and a second acetic acid stream more enriched with acetic acid than the first acetic acid stream;
recycling at least a portion of the aqueous phase and/or organic phase in the first overhead stream to a reaction vessel; and
separating and removing crotonaldehyde by treating at least another portion of the aqueous phase and/or organic phase by a distillation column;
wherein a potassium permanganate test value of the second acetic acid stream is more than 50 minutes; and
wherein with respect to a reflux ratio of the first distillation column, when only the aqueous phase is refluxed to the first distillation column, a reflux ratio of the aqueous phase is not less than 2, when only the organic phase is refluxed, a reflux ratio of the organic phase is not less than 1, and when both the aqueous phase and the organic phase are refluxed, a total reflux ratio of the aqueous phase and the organic phase is not less than 1.5; and when removing the crotonaldehyde, the distillation column is operated such that all of the following conditions (i) to (iii) are satisfied:
(i) the reflux ratio of the distillation column is not less than 0.01;
(ii) a ratio of a crotonaldehyde concentration in ppm by mass in a distillate liquid of the distillation column to a crotonaldehyde concentration in ppm by mass in a charging mixture, former/latter, is less than 1; and
(iii) a ratio of a crotonaldehyde concentration in ppm by mass in a bottom fraction of the distillation column to the crotonaldehyde concentration in ppm by mass in the charging mixture, former/latter, is more than 1.
US Pat. No. 10,429,288

ANALYTICAL ULTRACENTRIFUGATION FOR CHARACTERIZATION OF RECOMBINANT VIRAL PARTICLES

Genzyme Corporation, Cam...

1. A method of characterizing a preparation of recombinant adeno-associated viral (AAV) particles comprising the steps ofa) subjecting the preparation to analytical ultracentrifugation under boundary sedimentation velocity conditions wherein the sedimentation of recombinant AAV particles is monitored at time intervals,
b) plotting the differential sedimentation coefficient distribution value (C(s)) versus the sedimentation coefficient in Svedberg units (S), and
c) integrating the area under each peak in the C(s) distribution to determine the relative concentration of each peak, wherein each peak represents a species of recombinant AAV particle.
US Pat. No. 10,426,726

MEDICAL CHEWING GUM

1. A medical chewing gum comprising gum base components, chewing gum components, gum base polymers as part of the gum base components and nicotine,wherein the gum base polymers of the chewing gum are synthetic,
the gum base polymers comprising a combined amount of polyvinyl acetate and vinyl laurate-vinyl acetate copolymer of more than 90% by weight of the gum base polymers,
wherein the combined amount of polyvinyl acetate and vinyl laurate-vinyl acetate copolymer includes 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer, and
wherein the chewing gum contains no polyterpene resins and no resins based on gum rosin, wood rosin or tall oil resin,
whereby nicotine release is increased compared to a conventional nicotine chewing gum comprising natural resins having a similar level of burning.
US Pat. No. 10,428,262

NANOPARTICLE MODIFIED FLUIDS AND METHODS OF MANUFACTURE THEREOF

BAKER HUGHES, A GE COMPAN...

1. A nanoparticle modified fluid comprising:first nanoparticles that are surface modified to increase a viscosity of the nanoparticle modified fluid and that have at least one dimension that is less than or equal to about 100 nanometers;
second nanoparticles that are surface modified to increase a viscosity of the nanoparticle modified fluid and that have at least one dimension that is less than or equal to about 100 nanometers, the first nanoparticles being different from the second nanoparticles, the first and second nanoparticles having different functional groups, wherein the first nanoparticles are surface modified with epoxy groups and the second nanoparticles are surface modified with carboxyl groups; and
a liquid carrier comprising water;
wherein
the first and second nanoparticles each independently comprises carbonaceous nanoparticles, metal oxide nanoparticles, metal nanoparticles, polyhedral oligomeric silsesquioxane nanoparticles, clay nanoparticles, silica nanoparticles, boron nitride nanoparticles or a combination comprising at least one of the foregoing nanoparticles provided that where at least one of the first and second nanoparticles are the carbonaceous nanoparticles comprising carbon nanotubes, graphite nanoparticles, graphene nanoparticles, fullerenes, or a combination comprising at least one of the foregoing carbonaceous nanoparticles;
at least one of the first and second nanoparticles has an aspect ratio greater than 5;
the nanoparticle modified fluid exhibits a viscosity above that of a comparative nanoparticle modified fluid that contains the same nanoparticles but whose surfaces are not modified, when both nanoparticle modified fluids are tested at the same shear rate and temperature; and
the sum of the weight of the first and second nanoparticles is about 0.1 to about 2 wt. %, based on the total weight of the nanoparticle modified fluid, and the nanoparticle modified fluid has a viscosity increase of about 2 to about 6 orders of magnitude when the shear rate is decreased from 1,000 seconds?1 to 0.1 second?1.
US Pat. No. 10,428,007

METHOD FOR PRODUCING UNSATURATED ALDEHYDE AND UNSATURATED CARBOXYLIC ACID

LG CHEM, LTD., Seoul (KR...

1. A method for producing unsaturated aldehydes and unsaturated carboxylic acids corresponding to a raw material in which at least one compound selected from propylene, isobutylene, t-butyl alcohol, and methyl-t-butyl ether is added as the raw material and subjected to gas phase contact oxidation with molecular oxygen or a molecular oxygen-containing gas, using a fixed-bed multistage heat medium circulating type of multi-tubular shell-and-tube reactor filled with a catalyst,wherein the multistage heat medium circulating type of multi-tubular shell-and-tube reactor includes a cylindrical shell, a plurality of tube sheets for separating the inside of the shell into a plurality of independent spaces, a baffle for dividing the plurality of independent spaces inside the shell into two spatially continuous zones, and a plurality of reaction tubes fixed to the inside of the shell while penetrating through the plurality of tube sheets and the baffle,
wherein, in the plurality of independent spaces inside the shell, heat transfer to the reaction tube is performed independently at a temperature of 280 to 400° C. by the flow of an independent heat medium,
wherein at least four spatially continuous fixed catalyst layer zones exist in the reaction tube, the fixed catalyst layer zones have high activity in the direction from an inlet to an outlet of the reaction tube, and the fixed catalyst layer zones include first to fourth fixed catalyst layer zones, and
wherein a length (L) and an outer diameter (D) of the catalyst decreases from the first to the fourth fixed catalyst layer zones.
US Pat. No. 10,426,728

SYNERGISTIC LIPOSOMAL FORMULATION FOR THE TREATMENT OF CANCER

Council of Scientific and...

1. A synergistic liposomal formulation for the treatment of cancer, wherein said synergistic liposomal formulation consists of drug-free phosphatidylcholine (PC) and stearylamine (SA) liposomes, and camptothecin (CPT), doxorubicin (DOX), or combinations thereof, and wherein phosphatidylcholine, stearylamine, and camptothecin w/w molar ratio in said synergistic liposomal formulation is 7(PC):2(SA):0.7(CPT) or wherein phosphatidylcholine, stearylamine, and doxorubicin w/w molar ratio in said synergistic liposomal formulation is 7(PC):2(SA):0.5(DOX).
US Pat. No. 10,428,521

MASONRY BLOCK HAVING A CAVITY WEB

King Fahd University of P...

1. A masonry block with a cavity web, comprising:5-10 wt % cement;
75-80 wt % of an aggregate, which is not crumb rubber;
5-8 wt % water;
5-10 wt % crumb rubber relative to the total weight of the masonry block;
wherein the crumb rubber is in the form of coarse particles having a particle size of 1.5-5 mm, fine particles having a particle size of 50-250 ?m, or a mixture of the coarse particles and the fine particles; and
at least one of cement kiln dust and limestone powder, wherein the limestone powder has an average particle size of from 1 to 50 ?m,
wherein the aggregate is at least one selected from the group consisting of a crushed recycled concrete material and crushed limestone having an average particle size of greater than 1 millimeter, and
wherein the masonry block has a rectangular form with a front face, a back face, a first end face and a second end face forming a face perimeter surrounding a plurality of interior cavities separated by a web.
US Pat. No. 10,431,851

NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY AND METHOD FOR MANUFACTURING THE SAME

NISSAN MOTOR CO., LTD., ...

1. A non-aqueous electrolyte secondary battery comprising a power generating element including:two electrodes having different polarities, each of the electrodes including an active material layer formed on a current collector; and
an electrolyte layer positioned between the electrodes,
wherein the active material layer of at least one of the electrodes contains an active material and a conductive member made from an electron conducting material,
the active material layer has a first principal surface which comes into contact with the electrolyte layer, and a second principal surface which comes into contact with the current collector,
at least a part of the conductive member forms a conductive path electrically connecting the first principal surface to the second principal surface, and the conductive path is in contact with the active material in a periphery of the conductive path,
at least a part of a surface of the active material is coated with a coating agent that includes a coating resin and a conduction assisting agent,
an electrolyte solution contained in the electrolyte layer or the electrodes is a gel phase electrolyte,
the coating resin has a tensile elongation at break of 10% or more in a saturated liquid absorption state, and
the active material layer of at least one of the electrodes does not contain a binder.
US Pat. No. 10,426,729

FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY

Biogen Chesapeake LLC, C...

1. A method of treating a patient suffering from stroke, hemorrhage, neuronal cell swelling, traumatic brain injury, spinal cord injury, organ ischemia, myocardial infarction, or sepsis, comprising administering to said patient a reconstituted pharmaceutical formulation comprising a lyophilized composition that comprises:a) glibenclamide or a pharmaceutically acceptable salt thereof,
b) at least one substantially pharmaceutically inert compound selected from the group consisting of glucose, fructose, mannose, galactose, mannitol, sorbitol, lactose, trehalose, sucrose, sodium chloride and potassium chloride, and
c) one or more alkali bases,wherein the lyophilized composition contains said one or more alkali bases in an amount sufficient such that when said lyophilized composition is reconstituted in deionized water at a concentration of about 0.2 mg/mL to about 1.0 mg/mL to form said reconstituted pharmaceutical formulation, its pH is greater than 8, andwherein the lyophilized composition is stable for at least 3 months at 25° C. and 60% relative humidity.
US Pat. No. 10,431,853

RECHARGEABLE BATTERY FEATURES AND COMPONENTS

Apple Inc., Cupertino, C...

13. A battery comprising:a housing characterized by a first end and a second end opposite the first end, wherein the housing comprises a circumferential indentation proximate the first end, wherein the housing defines a first interior region between the first end and the circumferential indentation, and wherein the housing defines a second interior region between the circumferential indentation and the second end;
a set of electrodes located within the housing, wherein the set of electrodes is positioned within the second interior region of the housing;
a cap at least partially contained within the first interior region of the housing, wherein the cap is characterized by a first surface facing the set of electrodes;
a first electrode tab coupled with the set of electrodes at a first end of the electrode tab, wherein a first surface of the electrode tab is coupled with a surface of the cap at a second end of the electrode tab, wherein the second end of the electrode tab is contained within an insulative material, wherein a first window is defined within the insulative material along the first surface of the electrode tab, and wherein the first end of the electrode tab is characterized by chamfered edges;
a second electrode tab coupled between the set of electrodes and an interior surface of the housing, wherein the electrode tab is coupled with the housing in the second interior region proximate the circumferential indentation; and
a first insulator positioned within the housing, wherein the first insulator extends across the circumferential indentation from the cap to the set of electrodes, wherein the first insulator is characterized by a first outer radius at a first end proximate the cap, and wherein the first insulator is characterized by a second outer radius greater than the first outer radius at a second end proximate the set of electrodes.
US Pat. No. 10,426,731

METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF

TISSUETECH, INC., Miami,...

1. A fetal support tissue powder product produced by a process consisting essentially of:a) first, lyophilizing a fetal support tissue comprising amniotic membrane, chorion, or a combination thereof from frozen or previously frozen placenta to produce lyophilized fetal support tissue; and
b) second, grinding the lyophilized fetal support tissue to generate a fetal support tissue powder product.
US Pat. No. 10,426,733

PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB

Synthon B.V., Nijmegen (...

1. A tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, wherein:ibrutinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9°, 18.2°, 19.2°, 19.6° and 23.0°, measured using a Cu K? radiation, and
the composition is free of surfactant, and
the composition exhibits a dissolution rate of at least 65% in 20 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 (+1% polysorbate 20) at 37° C., 75 rpm and/or in 900 ml phosphate buffer pH 6.8 (+3% polysorbate 20) at 37° C., 75 rpm in a USP apparatus II.
US Pat. No. 10,426,734

TASTE MASKING DRUG FORMULATIONS

ORBIS BIOSCIENCES, INC., ...

1. A composition comprising: a microcapsule comprising a core portion and a shell portion, wherein the core portion comprises an active pharmaceutical ingredient and a hydrophilic excipient, wherein the shell portion comprises a mixture of a hydrophobic matrix and from about 1% to 25% by weight of a pH-responsive material, wherein the pH-responsive material is insoluble at a pH of greater than 5.0 or is otherwise insoluble in saliva and is soluble at a pH of less than 5.0, the balance of the shell portion comprising the hydrophobic matrix, wherein the hydrophobic matrix comprises one or more hydrophobic matrix components, wherein at least one of the hydrophobic matrix components is a wax or a lipid, wherein the shell portion encapsulates the core portion.
US Pat. No. 10,428,271

COMPOSITIONS AND METHODS FOR SELECTIVELY ETCHING TITANIUM NITRIDE

Entegris, Inc., Billeric...

1. A composition comprising: at least one oxidizing agent, an etchant, at least one activator present in an amount ranging from about 0.01 percent to about 10 percent by weight, and at least one solvent, wherein the at least one activator comprises a species selected from the group consisting of acetic acid, ammonium acetate, sodium acetate, potassium acetate, phosphonium acetate, ammonium butyrate, ammonium trifluoroacetate, amino acids, phosphoric acid, diammonium monohydrogen phosphate, ammonium dihydrogen phosphate, bis(tetramethylammonium) monohydrogen phosphate, disodium monohydrogen phosphate, sodium dihydrogen phosphate, dipotassium monohydrogen phosphate, potassium dihydrogen phosphate, ditetraalkylammonium monohydrogen phosphate, ditetraalkylammonium dihydrogen phosphate, diphosphonium monohydrogen phosphate, phosphonium dihydrogen phosphate, ammonium phosphonate, sodium phosphonate, potassium phosphonate, phosphonium phosphonate, and combinations thereof, wherein when in contact with a surface of a microelectronic device, the composition selectively removes titanium nitride and/or photoresist material from the surface of the microelectronic device without removing low-k dielectric material.
US Pat. No. 10,426,736

DELIVERING FUNCTIONAL NUCLEIC ACIDS TO MAMMALIAN CELLS VIA BACTERIALLY-DERIVED, INTACT MINICELLS

ENGENEIC MOLECULAR DELIVE...

1. A composition comprising:(a) a first intact, bacterially derived minicell that contains a a functional nucleic acid molecule or a plasmid comprising a segment that encodes a functional nucleic acid molecule, wherein the functional nucleic acid molecule targets (i) a transcript encoding a protein that contributes to apoptosis resistance in tumor cells or (ii) a transcript encoding a protein that contributes to neoplasticity in tumor cells;
(b) a second intact, bacterially derived minicell that is separate from the first minicell and that contains a drug; and
(c) a pharmaceutically acceptable carrier for each of (a) and (b).
US Pat. No. 10,431,347

MASTERBATCHES FOR PREPARING COMPOSITE MATERIALS WITH ENHANCED CONDUCTIVITY PROPERTIES, PROCESS AND COMPOSITE MATERIALS PRODUCED

1. A masterbatch for use in a process of preparing a composite material, the masterbatch comprising a blend of a first amorphous polymer with carbon nanotubes, at least 5% by weight of carbon nanotubes based on the total weight of the masterbatch as determined according to ISO 11358, and having a high load melt flow index HLMI1 of less than 40 g/10 min determined at 200° C. under a load of 21.6 kg according to ISO1133, the masterbatch being characterized in that the first amorphous polymer has a melt flow index MFI1 of at least 10 g/10 min determined at 200° C. under a load of 5 kg according to ISO1133H, wherein the first amorphous polymer is selected from the group consisting of polystyrene, modified-polystyrene, acrylonitrile-butadiene-styrene, polycarbonate, styrene acrylonitrile, poly(methyl methacrylate), poly(vinyl chloride), polybutadiene, polybutylene terephthalate, poly(p-phenylene oxide), polysulfone, polyethersulfone, polyethylenimine, polyphenylsulfone, acrylonitrile styrene acrylate and any combination thereof, wherein the masterbatch comprises at least 80% by weight of the first amorphous polymer, and wherein the masterbatch comprises a surface resistivity of at most 1×102 Ohm/sq as determined according to CEI 60167.
US Pat. No. 10,429,300

SURFACE PLASMON RESONANCE APPROACH TO MONITOR PROTEIN-LIGAND INTERACTIONS

The Johns Hopkins Univers...

1. A method of identifying a ligand that binds to a paddle motif peptide, the method comprising:a) contacting a paddle motif peptide immobilized on a sensor chip with a test molecule, wherein the paddle motif peptide comprises SEQ ID NO: 2 or SEQ ID NO: 4;
b) detecting binding of the ligand and the paddle motif peptide using surface plasmon resonance (SPR), thereby identifying the test molecule as a ligand that binds the paddle motif peptide.
US Pat. No. 10,426,738

POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE

ModernaTX, Inc., Cambrid...

1. A messenger RNA (mRNA) comprisingan open reading frame (ORF) encoding the human methylmalonyl-CoA mutase (MCM) polypeptide of SEQ ID NO:213, wherein the ORF is at least 99% identical to the nucleotide sequence of SEQ ID NO:732.
US Pat. No. 10,431,349

METHOD FOR MAKING CROSSLINKED FLUOROPOLYMER COMPOSITIONS CONTAINING LOW LEVEL OF EXTRACTABLE FLUORIDES

Daikin America, Inc., Or...

1. A method of making a crosslinked ethylene tetrafluoroethylene (ETFE) copolymer with enhanced abrasion resistance and heat resistance, the method comprising:(a) providing a composition comprising:
(i) a fluoropolymer fraction consisting essentially of ETFE;
(ii) a metal oxide selected from the group consisting of ZnO and MgO; and
(iii) at least 1% w/w triallyl isocyanurate (TAIC) as a crosslinking agent; and
(b) exposing the composition to at least about 5 Mrad (50 kGy) ionizing radiation; wherein the level of extractable fluoride ions in the crosslinked ETFE copolymer is less than about 150 ppm w/w.
US Pat. No. 10,427,251

FINE SILVER PARTICLE DISPERSION, FINE SILVER PARTICLES, AND METHOD FOR PRODUCING SAME

BANDO CHEMICAL INDUSTRIES...

1. A fine silver particle dispersion, which comprisesfine silver particles,
a short chain amine having 5 or less carbon atoms and
a highly polar solvent,
wherein a partition coefficient log P of the short chain amine is ?1.0 to 1.4 and
wherein the short amine is an alkoxyamine.
US Pat. No. 10,429,302

OPTICAL ANALYSES OF PARTICLES AND VESICLES

Scintillon Institute for ...

1. A method of analyzing particles in a sample, the method comprising:(a) contacting a sample comprising the particles with one or more optically detectable labels, thereby forming a staining solution, wherein:
the one or more optically detectable labels comprise a surface area probe or volume probe, wherein the surface area probe or volume probe interacts with the particles stoichiometrically with respect to particle surface area or volume, respectively, thereby forming particles comprising particle-associated surface area probe or particle-associated volume probe, wherein the optical signal from the particle-associated surface area or volume probe is proportional to the surface area or volume, respectively, of the particle;
and
(b) without physical separation or isolation of the particles, detecting the optical signal of the one or more particle-associated optically detectable labels generated in(a), thereby analyzing the particles in the sample.
US Pat. No. 10,426,740

COMPOSITIONS AND METHODS TO INHIBIT STEM CELL AND PROGENITOR CELL BINDING TO LYMPHOID TISSUE AND FOR REGENERATING GERMINAL CENTERS IN LYMPHATIC TISSUES

AVM Biotechnology, LLC, ...

1. A method to augment the number of circulating autologous or allogeneic stem cells that can be attracted to a damaged tissue or organ comprising:administering a therapeutic agent that contains dexamethasone base at a dose between about 3 mg/kg and 26 mg/kg to a subject having a damaged tissue or organ and active germinal centers within their lymphoid tissue, prior to or in conjunction with the administration of autologous or allogeneic stem cells such that the stem cells reach the circulation of the subject, wherein said therapeutic agent inhibits binding of the stem cells to germinal centers within said lymphoid tissue, wherein the therapeutic agent does not block the binding of the stem cells to the damaged organ or tissue, thereby augmenting the numbers of circulating stem cells that can be attracted to the target tissue or organ as compared to the numbers of circulating autologous and allogeneic stem cells in a subject without administering the therapeutic agent.
US Pat. No. 10,429,304

APPARATUS AND METHODS FOR IMAGING AND MODIFICATION OF BIOLOGICAL SAMPLES

PerkinElmer Singapore PTE...

1. A method of modifying a biological sample comprising a mixed population of cells by enriching the sample with respect to cells of interest, comprising the steps of:(a) providing a sample comprising a plurality of cells which include a photosensitive compound that can be induced by light irradiation to inactivate or kill at least part of the respective cell;
(b) acquiring a time sequence of images of the plurality of cells;
(c) identifying cells of interest in the sample images from said plurality of cells by analysis of the sequence of images acquired in step (b) by an image processing arrangement, the identification of cells of interest being based on detection of changes in the images indicating a predetermined event involving those cells occurring during the time sequence of images, wherein the cells are identified as of interest by reference to images or data relating to the sample and acquired using a different imaging modality to that employed in step (b);
(d) selecting cells from said plurality of cells other than the cells identified in step (c); and
(e) irradiating only those cells selected in step (d) by selectively directing a light beam to the selected cells to induce the photosensitive compound therein to inactivate or kill at least part of those cells, and to enrich the sample with respect to the cells of interest for further analysis.
US Pat. No. 10,428,278

METHOD AND SYSTEM FOR PRODUCING AROMATIC HYDROCARBONS FROM A RENEWABLE RESOURCE

Chevron Phillips Chemical...

1. A method for producing a bio-derived aromatic hydrocarbon, comprising:a) contacting a biomass with hydrogen in the presence of a hydrodeoxygenation catalyst in at least one hydrodeoxygenation reactor unit, under conditions that produce a bio-derived feedstock further comprising paraffinic, naphthenic, and/or olefinic hydrocarbons;
b) introducing the bio-derived feedstock into at least one aromatization reactor unit and contacting the bio-derived feedstock with an aromatization catalyst under conditions that produce an aromatic hydrocarbon and hydrogen; and
c) providing at least a portion of the hydrogen produced in the at least one aromatization reactor to the at least one hydrodeoxygenation reactor for contacting the biomass,
wherein the biomass comprises a cellulose, a sugar, a starch, a lignocellulose, a hemicellulose, a lignin, or combinations thereof.
US Pat. No. 10,426,743

TOPICAL PHARMACEUTICAL COMPOSITIONS

DERMAVANT SCIENCES GMBH, ...

1. A method of treating an inflammatory disease or disorder in a patient in need thereof, the method comprising administering to said patient a topical pharmaceutical oil-in-water emulsion composition comprising:3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof in an amount of about 0.05% to about 2% by weight, based on the total weight of the composition;
an oil phase comprising medium chain triglycerides of a carbon length from six to twelve carbons in an amount of about 2% to about 30% by weight, based on the total weight of the composition;
a water phase;
a surfactant in an amount of about 1% to about 20% by weight, based on the total weight of the composition, wherein the surfactant comprises at least one non-ionic emulsifying wax NF; and
a dermatologically acceptable excipient selected from the group consisting of an antioxidant, a pH adjusting agent, a chelating agent, a preservative, a co-solvent and combinations thereof;
wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof is solubilized in the oil phase and is the only active ingredient in the oil phase;
wherein the oil phase is substantially free of petrolatum and mineral oil;
wherein the oil-in-water emulsion is homogeneous; and
wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns.
US Pat. No. 10,428,023

HETEROCYCLIC COMPOUND AND USE THEREOF

Takeda Pharmaceutical Com...

1. N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3?,5?-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide or a salt thereof.
US Pat. No. 10,428,279

ELECTROLYZED WATER-AMINE COMPOSITIONS AND METHODS OF USE

1. A method of killing sulphate reducing microorganisms or microorganisms which can generate hydrogen sulphide, comprising the step of contacting the microorganism with a treatment fluid comprising a reaction product of electrolyzed water and an amine.
US Pat. No. 10,429,306

SURFACE PLASMON RESONANCE FLUORESCENCE ANALYSIS DEVICE AND SURFACE PLASMON RESONANCE FLUORESCENCE ANALYSIS METHOD

KONICA MINOLTA, INC., To...

1. A surface plasmon resonance fluorescence analysis device to which an analysis chip including a prism having a metal film provided on one surface of the prism is attached, and in which the metal film is irradiated with excitation light through the prism to excite a fluorescence material for labelling a substance to be detected on the metal film and fluorescence emitted from the fluorescence material is detected to detect presence or an amount of the substance to be detected, the surface plasmon resonance fluorescence analysis device comprising:a chip holder configured to detachably hold the analysis chip;
a light source configured to emit excitation light;
an angle adjusting section configured to adjust an incident angle of the excitation light with respect to the metal film to irradiate the metal film with the excitation light through the prism at a predetermined incident angle;
a first light sensor configured to detect fluorescence emitted from the fluorescence material;
a light reception optical system configured to guide light emitted from the metal film to the first light sensor;
an excitation light reflection filter disposed in the light reception optical system, and configured to reflect light having a wavelength same as that of the excitation light emitted from the light source in the light emitted from the metal film;
a second light sensor configured to detect the light reflected by the excitation light reflection filter; and
a control section configured to control the angle adjusting section; wherein
the control section controls the incident angle of the excitation light with respect to the metal film to be adjusted by the angle adjusting section on a basis of a detection result of the light obtained by the second light sensor.
US Pat. No. 10,426,744

ANTI-FUNGAL COMPOSITIONS FOR TREATING NAILS AND METHODS FOR FABRICATING AND USING THEREOF

Harrow Health, Inc., San...

1. A pharmaceutical composition for treating, mitigating or preventing fungal nail diseases, disorders or pathologies, the composition consisting of:(a) a therapeutically effective quantity of an antifungal component consisting of:
(a1) at least one functionalized allylamine compound;
(a2) at least one functionalized triazole compound; and
(a3) at least one functionalized imidazole compound;
(b) a therapeutically effective quantity of at least one pharmaceutically acceptable penetration enhancing compound selected from the group consisting of ibuprofen and ?-cyclodextrin; and
(c) at least one pharmaceutically acceptable excipient that is compatible with the antifungal component and the penetration enhancing compound, wherein the pharmaceutically acceptable excipient is selected from group consisting of glycol and benzyl alcohol,
wherein the composition has a pH in a range between about 2.0 and 6.5, and wherein the composition is formulated in a form that is suitable for topical administration.
US Pat. No. 10,428,280

METHOD FOR MANUFACTURING OF MULTI-LEVEL PORE ZEOLITE AND UTILIZATION AS CATALYST FOR HYDROISOMERIZATION OF NORMAL PARAFFINS OF MULTI-LEVEL PORE ZEOLITE PREPARED THEREBY

S-OIL CORPORATION, Seoul...

1. A method for preparing a multi-level pore zeolite containing silicon, aluminum, and phosphorus, comprising:(A) mixing a silicon precursor, an aluminum precursor, a phosphorus precursor, a structure directing agent and water;
(B) adding phenylphosphonic acid, carbon black or a mixture thereof to the mixture prepared in (A) and mixing the same;
(C) crystallizing the mixture prepared in (B) by heat-treating the same; and
(D) calcining the crystallization product,
wherein the multi-level pore zeolite has 10-30 vol % of micropores having a diameter of 0.1-1.9 nm based on the volume of total pores, 50-70 vol % of mesopores having a diameter of 2.0-50.0 nm based on the volume of total pores and 5-20 vol % of macropores having a diameter of 50.1-60.0 nm based on the volume of total pores.
US Pat. No. 10,427,001

METHOD AND APPARATUS FOR PREDICTING THE LIKELY SUCCESS OF GOLF SWINGS

Singleshot Entertainment,...

1. A method of predicting the likelihood of a golf swing or consecutive swings sinking a ball in a hole prior to the swing or consecutive swings comprised of the steps of:a) selecting a post tee off swing or post tee off consecutive swings in a golf game;
b) setting up a communication enabled data processing facility linked to a database of historical play information including at least ball position and golf course to calculate odds of success of the upcoming swing and/or subsequent swings,
c) placing electronic communication enabled ball position identifying equipment at a functional distance and remote location relative to the ball involved in the subject swing or swings,
d) activating the electronic communication enabled ball position identifying equipment so as to precisely determine pre-swing ball position and broadcasting this information to the processing facility in real time,
e) comparing the real time pre-swing ball position information received at the processing station with the database of prior ball positions in order to calculate the odds of the upcoming swing or swings terminating in a hole.
US Pat. No. 10,428,281

TRANSITION METAL TUNGSTEN OXY-HYDROXIDE

UOP LLC, Des Plaines, IL...

1. A conversion process comprising contacting a feed with a catalyst at conversion conditions to give at least one product, the catalyst comprising the decomposition product of the decomposition by sulfidation of a metal tungsten oxy-hydroxide material having the formula:Sa(NH4)bM(OH)xWyOz where ‘S’ is a sugar selected from glucose, fructose, galactose, lactose, maltose, sucrose, and mixtures thereof; ‘a’ varies from 0.001 to 5; ‘b’ varies from 0.1 and 3 ‘M’ is a metal selected from Mg, Mn, Fe, Co, Ni, Cu, Zn, and combinations thereof; ‘x’ varies from 0.1 to 2; ‘y’ varies from 0.1 to 4; z is a number which satisfies the sum of the valences of M, b, x and y; the material having a poorly crystalline diffraction pattern showing a broad peak between d-spacing 4.45-2.25 ?.
US Pat. No. 10,426,746

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES

OVID THERAPEUTICS INC., ...

1. A method of treating Fragile X syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a biguanide or a pharmaceutically acceptable salt thereof, the biguanide selected from the group consisting of metformin, buformin and phenformin, wherein the method provides improvement in one or more symptoms of Fragile X syndrome in the patient.
US Pat. No. 10,429,309

APPARATUS FOR SIMULTANEOUS DETECTION OF AMINES AND THIOLS

ALT BIOSCIENCE, LLC, Lex...

1. An apparatus for the simultaneous detection of amines and thiols, the apparatus comprising a thiol-detection reagent and an amine-detection reagent immobilized onto one or a plurality of pad matrices, wherein the amine-detection reagent comprises phthaldialdehyde (OPA) or fluorescamine, and wherein the one or a plurality of pad matrices is affixed to a plastic backing.
US Pat. No. 10,427,003

GOLF BALL HAVING AT LEAST ONE LAYER CONSISTING OF A MIXTURE OF A THERMOSET OR THERMOPLASTIC COMPOSITION AND A PLURALITY OF ALKOXYLATED SILOXANE-SURFACE TREATED PARTICLES AND/OR POLYETHER-MODIFIED SILOXANE-SURFACE TREATED PARTICLES

Acushnet Company, Fairha...

1. A golf ball having a CoR of at least 0.700 and an Atti compression of at least about 50 and comprising at least one layer comprising a mixture of a polyurethane composition and a plurality of titanium dioxide particulates, wherein at least a portion of the plurality is surface-treated with alkoxylated siloxanes, polyether-modified siloxanes, or combinations thereof;wherein the plurality of titanium dioxide particulates is included in the mixture in an amount such that the cover layer has a specific gravity of from 0.5 to about 5.0 and greater than a specific gravity of the polyurethane composition; and
wherein the plurality of titanium dioxide particulates creates a specific gravity gradient within the cover layer.
US Pat. No. 10,428,283

REACTOR WITH STRIPPING ZONE

UOP LLC, Des Plaines, IL...

1. A hydrotreating process comprising:providing a feed stream to a hydrotreating vessel, where the hydrotreating vessel comprises an upper zone, an intermediate zone and a lower zone;
passing the feed stream through the upper zone of the hydrotreating vessel, wherein the upper zone includes at least one upper catalyst bed;
separating a gas from a liquid within the intermediate zone;
passing the gas separated within the intermediate zone out of the hydrotreating vessel, said step of passing the separated gas comprises passing the separated gas through a heat exchanger and separating the vapor and liquid phase in a separator and routing liquid effluent from the separator back to said intermediate zone of the hydrotreating vessel;
providing a stripping gas to the lower zone through a first gas line;
replacing gas separated within the intermediate zone in the lower zone with a replacement gas via a second gas line in the lower zone; and
passing the liquid within the intermediate zone to the lower zone, wherein the lower zone includes a packed section wherein the liquid is contacted in counter current fashion with the stripping gas to remove impurities;
passing the liquid through to at least one lower catalyst in the lower zone,
wherein the step of removing impurities involves removing hydrogen sulfide and ammonia; and further wherein the hydrogen sulfide and the ammonia are passed out of the hydrotreating vessel during said step of passing the gas separated out of the hydrotreating vessel.
US Pat. No. 10,426,748

COMPOSITIONS AND METHODS FOR TREATING CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES

Infirst Healthcare Limite...

1. A pharmaceutical composition comprising:a) a therapeutically effective amount of an ibuprofen;
b) less than about 20% by weight of the composition of a pharmaceutically-acceptable liquid polyethylene glycol (PEG) polymer; and
c) at least 50% by weight of the composition of pharmaceutically-acceptable glycerolipids comprising monoglycerides, diglycerides, and triglycerides;
wherein the pharmaceutical composition is formulated to have a melting point temperature of about 25° C. or higher.
US Pat. No. 10,427,004

GOLF BALLS INCORPORATING THERMOPLASTIC BLENDS(S) OF IONOMER(S), THERMOPLASTIC POLYMER(S), PGM REACTIVE CROSSLINKER(S), AND CATALYST(S)

Acushnet Company, Fairha...

1. A golf ball comprising a core and at least one layer comprising a thermoplastic blend of (i) at least one ionomer; (ii) at least one thermoplastic polyurethane; (iii) at least one reactive crosslinker consisting of maleic group-modified polymer(s), glycidyl (meth)acrylate-modified polymer(s), or combinations thereof (“PGM”); and (iv) at least one catalyst;wherein the ionomer is present in an amount of about 45 wt % or greater and the PGM is present in an amount of from about 2 wt % to about 35 wt %.
US Pat. No. 10,426,749

SAFFLOWER OIL EMULSION AS DIETARY SUPPLEMENT AND PREPARATION THEREOF

InnoVitamin Organics, LLC...

1. A drinkable dietary supplement for increasing metabolism in the form of a stable, spoonable, drinkable emulsion, wherein the dietary supplement consists of:a linoleic fatty acid rich safflower oil, wherein the linoleic fatty acid is in a range from approximately 70% to approximately 80% of the total safflower oil;
purified water mixed with the linoleic fatty acid rich safflower oil to form a purified water-safflower oil mixture; and
an emulsifier mixture added to the purified water-safflower oil mixture, wherein the combined emulsifier mixture and purified water-safflower oil mixture are blended under ambient conditions in a temperature range from approximately 21.1 degrees C. to approximately 25 degrees C. and at a pressure of one atmosphere to provide the dietary supplement having a smooth mouth-feel and a shelf-life of approximately 18 months.
US Pat. No. 10,426,750

AMINO ACID SUPPLEMENT FORMULATIONS

ThermoLife International,...

1. A supplement formulation for ingestion comprising:a nitrate of a compound selected from the group consisting of: agmatine, beta alanine, citrulline, creatine, glutamine, isoleucine, norvaline, ornithine, aspartic acid, cysteine, glycine, lysine, proline, tyrosine, and phenylalanine, wherein the nitrate of the compound is a salt of nitric acid (NO3?) or a mixed salt of nitric acid (NO3?); and
one or more additional components selected from the group consisting of: a binder, a colorant, and a flavoring agent,
wherein the supplement formulation is formulated to deliver an effective amount of the nitrate of the compound to ameliorate tolerance to dilator effects of nitrates, to increase bioabsorption of the compound, to increase the vasodilative characteristics of the compound, or to increase athletic performance in a human or animal.
US Pat. No. 10,427,006

GOLF BALL INCORPORATING AT LEAST ONE LAYER OF PLASTICIZED NEUTRALIZED ACID POLYMER COMPOSITION CONTAINING LOW MOLECULAR WEIGHT ACID WAX(ES) AS SOLE ACID POLYMER COMPONENT AND LOW MOLECULAR WEIGHT NON-ACID WAX(ES) IN THE NON-ACID POLYMER COMPONENT

Acushnet Company, Fairha...

1. A golf ball comprising at least one layer consisting of a plasticized neutralized acid polymer composition consisting of a mixture of: (a) at least one low molecular weight acid-containing wax; (b) at least one non-acid-polymer, of which at least one is a low molecular weight non-acid wax; (c) at least one organic acid or salt thereof; and (d) at least one plasticizer;wherein each low molecular weight acid-containing wax has a molecular weight of from about 500 to about 30,000;
wherein the mixture contains at least 70 percent of neutralized acid groups; and
wherein the mixture has a melt flow index of at least 0.5 g/10 min.
US Pat. No. 10,427,007

GOLF BALL COMPOSITIONS

Acushnet Company, Fairha...

1. A golf ball comprising an innermost core layer formed from a heterogeneous composition comprising a thermoplastic matrix and discrete particles dispersed within the matrix, wherein the discrete particles are formed from a crosslinked rubber composition having a Shore D hardness of 65 or greater, and wherein each of the discrete particles present in the composition has a particle size of from 0.030 mm to 2.38 mm, and wherein the discrete particles are present in the heterogeneous composition in an amount of 60 wt % or greater, based on the total weight of the heterogeneous composition.
US Pat. No. 10,428,288

PROCESS FOR CONVERTING A BIOMASS INTO AT LEAST ONE BIOCHAR

1. A method for transforming a biomass into at least one biochar, comprising the following steps of:(a) providing a ground and dried biomass, said biomass containing at least 30% of a lignocellulosic biomass, by mass relative to the dry weight of the ground and dried biomass and said biomass being in the form of particles with homogeneous dimensions and having a moisture content close to 0;
(b) heating progressively this biomass at a temperature higher than 140° C. and lower than 350° C., in an oxygen-free gas stream, at a pressure comprised between 1 and 40 bar until exothermic phenomenon takes off;
(c) allowing the exothermic reaction to proceed by maintaining the temperature in the 300-700° C. range and the pressure in the 1-40 bar range;
(d) cooling the biomass derived from step (c), at a temperature of at most 100° C., in an oxygen-free gas stream; and
(e) collecting the biochar,
said method being implemented without any supply of external inert gas.
US Pat. No. 10,428,290

DE-ICING LUBRICANT COMPOSITION

1. A de-icing lubricant composition, comprising:a. isopropyl alcohol comprising 60-90% of the composition by weight; and
b. mineral oil.
US Pat. No. 10,426,756

MULTIVITAMIN CAPABLE OF BENEFICIAL GENE REGULATION THROUGH MICRORNA (MIRNA)

PERFORMANCE LABS PTE. LTD...

1. A composition for modifying the expression of microRNAs comprising:one or more plant secondary metabolites capable of beneficially regulating different genes in the human genome by modifying the expression of one or more microRNAs, wherein the one or more plant secondary metabolites are selected and provided in an amount selected to target the modification of one or more specific microRNAs, wherein the composition comprises the plant secondary metabolites:
epigallocatechin gallate in an amount of 70-300 milligrams;
isoquercetin in an amount of 20-50 milligrams;
folic acid in an amount of 150-350 micrograms;
curcumin in an amount of 30-70 milligrams;
hesperidin in an amount of 30-70 milligrams;
grape polyphenols in an amount of 100-150 milligrams;
sulforaphane in an amount of 0.2-2 milligrams;
proanthocyanidins in an amount of 45-70 milligrams;
apple polyphenols in an amount of 65-90 milligrams; and
citrus bioflavonoids in an amount of 80-110 milligrams.
US Pat. No. 10,426,757

COMPOSITIONS AND METHODS FOR PROMOTING INTESTINAL STEM CELL AND/OR NON-STEM PROGENITOR CELL FUNCTION

Whitehead Institute for B...

1. A method of stimulating the proliferation and/or self-renewal of one or more intestinal stem cells in mammalian intestinal tissue in a subject, the method comprising contacting a population of cells in the mammalian intestinal tissue with an effective amount of a compound that increases the level and/or activity of peroxisome proliferator activated receptor delta (PPAR-?) or a PPAR-? target protein, thereby stimulating the proliferation and/or self-renewal of one or more intestinal stem cells, wherein the contacting of the population of cells with the effective amount of the compound occurs in a subject suffering a disease characterized by intestinal stem cells that require increased proliferation and/or self-renewal, wherein the compound comprises a PPAR-? agonist or a PPAR-? target protein agonist selected from the group consisting of a CPT1A agonist, a HMGCS2 agonist, and a FABP1 agonist.
US Pat. No. 10,428,037

METHOD FOR THE SYNTHESIS AND PURIFICATION OF ETHERS

The United States of Amer...

1. A method of purifying an ether, comprising:reacting a mixture comprising tetrahydrofurfuryl alcohol, about one-half equivalent of low work function element;
adding about one-half equivalent of a halide;
adding about one-half equivalent of low work function element and one-half equivalent of halide and reacting;
adding an excess amount of low work function element until unreacted low work function element is detected; and,
fractionally distilling said mixture to obtain the purified ether wherein said low work function element is an elemental metal or a metal hydride which has a ? of less than about 3.0 eV.
US Pat. No. 10,428,293

ENHANCED EXTREME PRESSURE LUBRICANT FORMULATIONS

Dow Global Technologies L...

1. A lubricant formulation comprising:a. at least 50 weight-percent of a hydrocarbon base oil;
b. five weight-percent or more and less than 50 weight-percent of an oil soluble polyalkylene glycol selected from a group consisting of monol, diol and triol initiated 1,2-butylene oxide homopolymers and monol initiated copolymers of 1,2-butylene oxide and propylene oxide; and
c. 0.1 weight-percent or more and five weight-percent or less of a sulfurized olefin, where weight-percent is based on total lubricant formulation weight.
US Pat. No. 10,428,038

SINGLE STEP PROCESS FOR THE SYNTHESIS OF FURFURYL ETHYL ETHER

COUNCIL OF SCIENTIFIC AND...

1. A single step process for the synthesis of furfuryl ethyl ether comprises refluxing the reaction mixture of furfuryl alcohol, ethanol and Zr incorporated SBA-15 catalyst at temperature in the range of 80 to 120° C. for the period in the range of 3 to 7 hrs to afford furfuryl ethyl ether, wherein selectivity of said reaction towards furfuryl ethyl ether is in the range of 85 to 95%.
US Pat. No. 10,428,294

CONTROLLED RELEASE MICROCAPSULES

ENCAPSYS, LLC, Appleton,...

1. A method of making microcapsules whose shell wall comprises on one surface a first (meth)acrylate polymer and on its other surface a second (meth)acrylate polymer, said first (meth)acrylate polymer derived from an aqueous phase (meth)acrylate polymer wall forming composition (I) and said second (meth)acrylic polymer derived from an oil phase (meth)acrylate polymer wall forming composition (II), both the aqueous phase (meth)acrylate polymer wall forming composition (I) and the oil phase (meth)acrylate polymer wall forming composition (II) comprising wall forming materials, and an intermediate region comprising an interpenetrating network and/or copolymer of the two wall forming compositions, said method comprising:(i) forming an oil-in-water or a water-in-oil emulsion of the two (meth)acrylate polymer wall forming compositions,
(ii) subjecting the emulsion to conditions for concurrently, at last in part, polymerizing the wall forming materials of each of the oil phase and aqueous phase, and
(iii) allowing the reaction to continue until the microcapsules of desired wall thickness are attained wherein said aqueous phase (meth)acrylate polymer wall forming composition (I) comprises one or more polyethylene glycol di(meth)acrylates, ethoxylated mono- or multi-functional (meth)acrylates, and/or (meth)acrylate monomers and/or oligomers.
US Pat. No. 10,426,759

USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

NOVARTIS AG, Basel (CH)

1. A compound which is a citrate salt of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide.
US Pat. No. 10,428,040

PROCESSES FOR THE ISOLATION OF A CANNABINOID EXTRACT AND PRODUCT FROM CANNABIS PLANT MATERIAL

1. A process for obtaining a cannabinoid extract from Cannabis plant material comprising:a) the step of providing a dispersion of material comprising cannabinoids derived from one or more Cannabis plants in an oil;
b) the step of isolating at least a portion of said cannabinoids from said dispersion to obtain a cannabinoid extract, wherein said step of isolating comprises one or both of:
A) stripping said dispersion under reduced pressure with a gaseous stripping medium to extract at least a portion of said cannabinoids from said dispersion into said gaseous stripping medium to obtain a vapour containing cannabinoids;
condensing at least part of said vapour to form a condensate; and
recovering a cannabinoid extract from said condensate; and/or
B) mixing said dispersion with a polar solvent, and forming a two-phase system with a first phase of said dispersion and a second phase of said polar solvent, wherein at least part of the cannabinoids is extracted into the second phase: isolating at least part of the second phase from the first phase; and wherein the extraction is optionally followed by
evaporating at least part of said isolated second phase to obtain a cannabinoid containing evaporation residue.
US Pat. No. 10,428,296

UNIT DOSE FABRIC SOFTENER

Colgate-Palmolive Company...

1. A unit dose fabric conditioner comprising a fabric conditioner composition contained within a water soluble pouch, wherein the composition is liquid at 25° C. and comprises:a) a cationic fabric softening active, wherein the cationic fabric softening active is at least one active chosen from esterquat, tallow esterquat, triolyeyl esterquat, and diolyeyl esterquat;
b) at least 50% by weight of the composition of a C3-C12 polyol that is liquid at 25° C.;
c) a C9-C15 alkoxylated alcohol having an average of 3 to 8 EO per mole and which is liquid at 25° C.;
d) a dispersing polymer for dispersing the cationic fabric softening active; and
encapsulated fragrance;
wherein the alkoxylated alcohol is present in an amount of 2.6 to 7.1% by weight of the composition; and
wherein the dispersing polymer is present in an amount of 1.6 to 5.8% by weight of the composition.
US Pat. No. 10,426,761

METHOD FOR TREATMENT OF DISEASE CAUSED OR AGGRAVATED BY MICROORGANISMS OR RELIEVING SYMPTOMS THEREOF

ARMS Pharmaceutical, LLC,...

1. A method for treating a viral upper respiratory infection or for treating a symptom of the viral upper respiratory infection, or a combination of both the disease being caused or aggravated by microorganisms, comprising:treating the viral upper respiratory infection, treating the symptom of the viral upper respiratory infection, or reducing the duration of the viral upper respiratory infection, or combinations thereof, by administering a barrier-forming composition in a therapeutically effective amount to a surface, the surface comprising a mammal mucosa, the mammal being infected with the viral upper respiratory infection or experiencing symptoms of the viral upper respiratory infection;
the barrier-forming composition comprising an antimicrobial;
forming a barrier coating on the surface that is active to kill or neutralize microorganisms encountered by the barrier coating;
wherein the barrier-forming composition is effective to reduce duration, frequency, or severity of one or more of cough, sore throat, and fever;
wherein the barrier-forming composition meets the following requirements:
about 0.0001%?C<0.4%;
about 0.07%?H?about 70%; and
0.0005% wherein all percentages are by weight of the total composition;
wherein C is a carbohydrate gum; H is a humectant; and A is the antimicrobial agent.
US Pat. No. 10,426,763

PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS

Bjoern Colin Kahrs, Coll...

1. A method of alleviating multiple sclerosis or a clinical symptom thereof or delaying the onset of multiple sclerosis or a clinical symptom thereof in a patient, comprising the co-administration of therapeutically effective amounts of an Nrf2 activator selected from the fumaric acid esters and salts thereof and a PPAR gamma agonist selected from glitazones and salt forms thereof to said patient.
US Pat. No. 10,428,043

GREEN OXIDATION CATALYTIC SYSTEM

TRUSTEES OF BOSTON UNIVER...

1. A reaction mixture comprisingan oxidation catalyst comprising a metal ion complexed with an ?-keto acid and a tridentate N,N,O-ligand;
a solvent, wherein the solvent is in contact with the oxidation catalyst; and
a substrate dissolved in the solvent, wherein the solvent and the substrate are different; and wherein the solvent is a polar or polar aprotic solvent.
US Pat. No. 10,426,764

ANTIHISTAMINE FOR USE IN TREATMENT OF BREAST CANCER

Belina Pharma AB, Helsin...

1. A method of treating breast cancer in a patient diagnosed with breast cancer, the method consisting of administering to the patient an effective amount of desloratadine, wherein the breast cancer is selected from the group consisting of positive and negative ER, PR, her2 breast cancer molecular subtypes, and invasive breast carcinomas, and wherein the patient is not diagnosed with a seasonal allergic condition.
US Pat. No. 10,426,765

PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA

CONARIS RESEARCH INSTITUT...

1. An oral pharmaceutical composition for positively influencing intestinal microbiota, comprising an active substance selected from the group consisting of nicotinic acid; nicotinamide; tryptophan; nicotinic acid esters; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP selected from N-formylkynurenine, L-kynurenine, 3-hydroxy-L-kynurenine, 3-hydroxyanthranilate, 2-amino-3-carboxymuconate semialdehyde, quinolinate, and beta-nicotinate D-ribonucleotide; a tryptophan dipeptide; or a combination of two or more thereof, formulated for selective release in the terminal ileum, the colon, or both, for topical efficacy in the terminal ileum, the colon, or both, where the intestinal microbiota to be influenced are located,wherein the oral pharmaceutical composition is formulated for oral administration and comprises (a) a matrix that comprises the active substance(s), wherein the matrix comprises one or more selected from microcrystalline cellulose, gelatin, and polyvinylpyrrolidone, and, optionally, (b) a coating, wherein the oral pharmaceutical composition selectively releases the active substance(s) in the terminal ileum, the colon, or both for topical efficacy in the terminal ileum, the colon, or both, to thereby positively influence intestinal microbiota.
US Pat. No. 10,426,766

CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND

1. A method of enhancing motility of the gastrointestinal tract in a human, the method comprising administering to the human a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and the crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide, wherein a single crystal of the sulfate salt, analyzed at a temperature of ?153±1° C., is characterized by an orthorhombic unit cell with dimensions a=6.824 ?, b=16.228 ?, c=24.202 ?, ?=?=?=90°; cell volume (V) of 2680.0 ?3, and a space group of P212121(#19).
US Pat. No. 10,428,302

ALKALINE MICROBIAL ENHANCED OIL RECOVERY

GEO FOSSIL FUELS, LLC, H...

1. A microorganism of the domain Archaea or bacteria, that is engineered to have at least one of the following properties: (i) being an obligatory alkaliphile, halo-alkaliphile or alkaline tolerant, (ii) being deficient in its ability to degrade short chain hydrocarbons of 12 carbons or less, and (iii) having the ability to produce surfactants, wherein the Archaea is of the genus Haloferax, and wherein the bacteria is selected from the group of genera consisting of Pseudomonas and Bacillus.
US Pat. No. 10,426,767

METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS

Kura Oncolofy, Inc., San...

1. A method of treating a CXCL12-expressing cancer in a subject, comprising administering a therapeutically effective amount of a farnesyltransferase inhibitor (FTI) to the subject, wherein the cancer is peripheral T-cell lymphoma (PTCL) or acute myeloid leukemia (AML).
US Pat. No. 10,428,304

METHOD FOR PRODUCING B CELL POPULATION

TOKYO UNIVERSITY OF SCIEN...

1. A method for producing a B cell population, comprising culturing B cells, in which the expression of a Bach2 gene has been increased, in the presence of a means for acting on CD40 and/or a BAFF receptor.
US Pat. No. 10,431,380

BIAXIALLY STRETCHED POLYPROPYLENE FILM FOR CAPACITOR

OJI HOLDINGS CORPORATION,...

1. A biaxially stretched polypropylene film for capacitors, obtained by biaxially stretching a polypropylene resin,the polypropylene film having a crystallite size of 122 ? or less as determined by the Scherrer's equation from the half width of the reflection peak from (040) plane of ?-crystal measured by a wide angle X-ray diffraction method, and
the polypropylene film having a value of birefringence ?Nyz with respect to a thickness direction of 7.0×10?3 or more and 10.0×10?3 or less as measured by an optical birefringence measurement.
US Pat. No. 10,426,770

PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE

Jubilant Generics Limited...

1. A process for the preparation of lurasidone or a pharmaceutically acceptable salt thereof, comprising the steps of:a) converting ((R,R)-cyclohexane-1,2-diyl)bis((1H-imidazol-1-yl)methanone) to trans(R,R)-1,2-bis(hydroxymethyl)cyclohexane,
b) converting trans(R,R)-1,2-bis(hydroxymethyl)cyclohexane obtained in step (a) to lurasidone, and
c) optionally converting lurasidone free base into its pharmaceutically acceptable salt.
US Pat. No. 10,428,306

METHOD AND SYSTEM FOR TISSUE TREATMENT WITH CRITICAL/SUPERCRITICAL CARBON DIOXIDE

Warsaw Orthopedic, Inc., ...

1. A method of decontaminating bone tissue, the method comprising: contacting the bone tissue having contaminants therein with carbon dioxide to decontaminate the bone tissue and form carbon dioxide having contaminants; collecting the carbon dioxide having contaminants; separating the contaminants from the collected carbon dioxide; and removing the contaminated carbon dioxide, purifying the contaminated carbon dioxide with supercritical fluid, liquefying the purified carbon dioxide and using liquid purified carbon dioxide as a cooling fluid.
US Pat. No. 10,428,307

METHOD FOR CONVERTING MESENCHYMAL STEM CELLS INTO ENDOTHELIAL CELLS BY USING SPECIFIC TRANSCRIPTION FACTORS

The Catholic University o...

1. An in vitro method for converting mesenchymal stem cells into endothelial cells, the method comprising the steps of:(a) introducing lentiviral vectors comprising Oct4, Nanog, Tal1, and LMO2 genes into the mesenchymal stem cells; and
(b) culturing the transduced mesenchymal stem cells on a gelatin-coated plate under culture conditions comprising endothelial cell growth medium EGM2 and SB431542, wherein said culturing induces the conversion of the mesenchymal stem cells into endothelial cells.
US Pat. No. 10,426,772

USE OF ERGOT ALKALOIDS AS AN ANTHELMINTIC AGENT

Regents of the University...

1. A method of inhibiting or treating parasitic flatworm infection in a vertebrate, comprising:administering an effective amount of a composition comprising one or more ergot alkaloids, one or more lysergic acid amides, or any combination thereof, wherein the ergot alkaloid is an agonist or partial agonist of Schistosoma serotonergic G-protein coupled receptor.
US Pat. No. 10,428,308

MESODERM AND DEFINITIVE ENDODERM CELL POPULATIONS

Icahn School of Medicine ...

1. A method of making a cell population enriched for endoderm cells comprising culturing pluripotent stem cells in the presence of activin or nodal, and Wnt, for a time sufficient to provide brach+/HNF3?+ cells, and culturing said brach+/HNF3?+ cells in the presence of activin and an inhibitor of Wnt signalling for a time sufficient to provide a cell population enriched for endoderm cells.
US Pat. No. 10,426,773

SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS

CASE WESTERN UNIVERSITY, ...

1. A method of treating an ocular disorder associated with light induced retinal degeneration, aberrant all-trans-retinal clearance, or reactive oxygen species generation in the retina of a subject, comprising:administering to the subject individually subtherapeutic amounts of two or more agents, wherein the two or more agents comprise an agent that inhibits and/or blocks the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade in ocular cells of the subject, and an agent that activates Gi-protein coupled receptors, wherein the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade is induced or triggered by light induced all-trans-retinal generation.
US Pat. No. 10,428,053

CO-CRYSTALS OF SGLT2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF

LAURUS LABS LIMITED, Hyd...

1. Co-crystals selected from the group consisting of co-crystals of canagliflozin and DL-pipecolic acid, co-crystals of canagliflozin and L-pipecolic acid, co-crystals of canagliflozin and D-pipecolic acid, co-crystals of dapagliflozin and DL-pipecolic acid, co-crystals of dapagliflozin and D-pipecolic acid, co-crystals of dapagliflozin and L-pipecolic acid, and co-crystals of empagliflozin and DL-pipecolic acid.
US Pat. No. 10,426,774

METHODS OF TREATING CANCER HAVING AN ACTIVE WNT/?-CATENIN PATHWAY

Dana-Farber Cancer Instit...

1. A method of treating a cancer in a subject in need thereof comprising (a) determining that the subject has a Wnt/?-catenin active cancer, and (b) administering to the subject a treatment consisting of a therapeutic amount of a YES1 inhibitor, wherein the YES1 inhibitor is a nucleic acid, an antibody or an organic molecule capable of decreasing protein expression from the YES1 gene or decreasing the phosphorylation activity of YES1 protein.
US Pat. No. 10,428,310

METHODS AND COMPOSITIONS FOR GENERATING OR MAINTAINING PLURIPOTENT CELLS

Regeneron Pharmaceuticals...

1. An in vitro culture comprising:(a) a population of nave human induced pluripotent stem cells (hiPSCs) that display a morphology characterized by compact, dome-shaped colonies; and
(b) a low osmolality medium comprising a base medium and supplements, wherein the low osmolality medium comprises:
(i) a leukemia inhibitory factor (LIF) polypeptide;
(ii) a glycogen synthase kinase 3 (GSK3) inhibitor; and
(iii) a MEK inhibitor;
wherein the low osmolality medium has an osmolality of about 200 mOsm/kg to about 250 mOsm/kg.
US Pat. No. 10,426,775

METHODS FOR TREATING FRIEDREICH'S ATAXIA WITH ETRAVIRINE

FRATAGENE THERAPEUTICS SR...

1. A method of treating Friedreich's ataxia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of etravirine or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,428,311

METHOD FOR ENHANCING ACTIVITY OF LAMININ FRAGMENTS AS CELL CULTURE MATRIX

OSAKA UNIVERSITY, Osaka ...

5. A solution for coating a culture surface of a cell culture vessel with a laminin fragment or a variant thereof,the solution containing a laminin fragment or a variant thereof each having an integrin binding activity and a protein that is neither a laminin nor a laminin fragment,
the laminin fragment or a variant thereof being present at a concentration of 5 ?g/mL or lower,
the protein that is neither a laminin nor a laminin fragment being present at a concentration which is 100-fold or more that of the laminin fragment or a variant thereof and is 500 ?g/mL or higher,
the protein that is neither a laminin nor a laminin fragment is gelatin or serum albumin,
wherein the laminin fragment is a laminin E8 fragment, and
wherein the variant is a chimeric molecule in which the laminin E8 fragment is conjugated with a cell adhesion molecule or a growth factor binding molecule.
US Pat. No. 10,426,776

METHOD FOR TREATING CANCER PATIENTS WITH SEVERE RENAL IMPAIRMENT

TAIHO PHARMACEUTICAL CO.,...

1. A method for treating cancer which is one of gastrointestinal cancer, large bowel cancer and breast cancer, comprising:detecting a creatinine clearance of a patient; and
orally administering to the patient with a creatinine clearance of less than 30 mL/min a combination drug comprising ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, a daily dose of 30 to 40 mg/m2/day as FTD-equivalent, divided into two to four portions for administration.
US Pat. No. 10,428,056

HETEROCYCLIC COMPOUND

Takeda Pharmaceutical Com...

1. A method for treating Alzheimer's disease, schizophrenia, cognitive impairment associated with schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Parkinson's disease, or dementia with Lewy bodies in a mammal, comprising: administering an effective amount of 8-chloro-6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclopentyl)-7-methyl-2,3-dihydro-4H-1,3-benzoxazin-4-one or a salt thereof to the mammal.
US Pat. No. 10,426,777

METHODS USED TO TREAT CANCER

The Translational Genomic...

1. A pharmaceutical composition comprising:a first active ingredient, wherein the first active ingredient is propentofylline or a pharmaceutically acceptable salt thereof; and
a second active ingredient, wherein the second active ingredient is a chemotherapeutic agent selected from the group consisting of: cis-diamminedichloro platinum (II) (cisplatin), doxorubicin, 5-fluorouracil, paclitaxel, topoisomerase inhibitor, and a targeted-therapy drug.
US Pat. No. 10,426,778

PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR DIFFUSE LARGE B-CELL LYMPHOMA

ONO PHARMACEUTICAL CO., L...

1. A method of treating B-cell non-Hodgkin's lymphoma comprising: administering to a human in need thereof a pharmaceutically effective amount of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof and at least one additional anticancer agent; wherein the at least one additional anticancer agent comprises a PI3K inhibitor, and wherein the PI3K inhibitor is CAL-101.
US Pat. No. 10,428,314

HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF

The United States of Amer...

1. A vector, comprising a heterologous nucleic acid molecule encoding at least 70 contiguous residues of the amino acid sequence of SEQ ID NO: 9 (GP).
US Pat. No. 10,426,779

INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY

VIRGINIA COMMONWEALTH UNI...

1. A method of treating a solid tumor in a subject, comprising administering to the subject a hypoxia-activated bioreductive agent and one or more hypoxia-inducing agents, wherein the one or more hypoxia-inducing agents comprise combretastatin or a combretastatin derivative, wherein the hypoxia-activated bioreductive agent is tirapazamine, wherein the hypoxia-activated bioreductive agent is administered before or concurrently with the one or more hypoxia-inducing agents, and wherein the administration is in an amount effective in inducing necrosis of the solid tumor after 3 days of the administration.
US Pat. No. 10,428,315

BACULOVIRUS-BASED PRODUCTION OF BIOPHARMACEUTICALS FREE OF CONTAMINATING BACULOVIRAL VIRIONS

GENETHON, Evry (FR)

1. A method for the production of a biopharmaceutical product, comprising:(a) infecting a biopharmaceutical-producing insect cell with at least one baculovirus, said at least one baculovirus comprising a genome coding for said biopharmaceutical product, and
(b) maintaining the biopharmaceutical-producing insect cell under conditions such that the biopharmaceutical product is produced,
wherein the genome of said at least one baculovirus is mutated to eliminate the expression of vp1054 or wherein said biopharmaceutical-producing insect cell comprises an expression control system allowing the inactivation of vp1054.
US Pat. No. 10,428,316

IMMORTALISED CHICKEN EMBRYO FIBROBLASTS

Intervet Inc., Madison, ...

1. A stably transfected immortalized chicken embryo fibroblast (CEF), wherein said immortalized CEF (i) expresses an SV40 T antigen, (ii) expresses a chicken telomerase (cTERT) under the control of a heterologous promoter, and (iii) does not comprise an exogenous retroviral Long Terminal Repeat (LTR) DNA.
US Pat. No. 10,426,781

ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGY DRUG

Sun Pharma Global FZE, S...

1. A powder for oral suspension, comprising: sonidegib, or a pharmaceutically acceptable salt thereof, in powder form, and a filler comprising microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharide, sucrose, dextrose, starch, mannitol, dextrose, or a mixture thereof, a glident comprising fumed silicon dioxide, sodium aluminosilicate, calcium silicate, powdered cellulose, colloidal silicon dioxide, microcrystalline cellulose, corn starch, sodium benzoate, calcium carbonate, magnesium carbonate, talc, metallic stearates, calcium stearate, magnesium stearate, zinc stearate, magnesium lauryl sulfate, and magnesium oxide, or a mixture of two or more thereof, a lubricant comprising magnesium stearate, colloidal silicon dioxide, talc, calcium stearate, stearic acid, PEG, glyceryl monostearate, potassium benzoate, sodium stearyl fumarate, glyceryl behenate, mineral oil, or a mixture of two or more thereof, or a combination of two or more of said filler, glident and lubricant.
US Pat. No. 10,428,317

LIGHT-EMITTING MOLECULES

Gene Stream Pty Ltd, Cit...

1. A method of modifying an isolated, synthetic, recombinant or purified copepod luciferase polypeptide comprising an amino acid sequence at least 80% identical to SEQ ID NO: 792 or SEQ ID NO: 2, the method comprisingaltering the copepod luciferase polypeptide such that it comprises a modification consisting of:(a) at least one BC motif, wherein B is selected from basic amino acid residues and C is a conserved cysteine or modified form thereof; and the BC motif is selected from the group consisting of BCA at C5, C6, and/or C9, BCA? at C5, C6, and/or C9, and BCAD at C5, C6, and/or C9, wherein ? is selected from a small amino acid residue or an acidic amino acid residue, A is alanine or modified form thereof, D is aspartate or a modified form thereof, and C5, C6, and C9 are conserved cysteines of consensus SEQ ID NO: 905;and at least one of:
(i) L, or modified form thereof, at at least one position corresponding to positions 85 or 98 of consensus SEQ ID NO: 905; and
(ii) a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at a position corresponding to position 85 of consensus SEQ ID NO: 905; or(b) at least one BC motif, wherein B is selected from basic amino acid residues and C is a conserved cysteine or modified form thereof; and the BC motif is selected from the group consisting of BCA at C5 and/or C9, BCAD at C5, and/or C9, and BCA at C5and/or C9, wherein ? is selected from a small amino acid residue or an acidic amino acid residue, A is alanine or modified form thereof, D is aspartate or modified form thereof, and C5, and C9 are conserved cysteines of consensus SEQ ID NO: 905,and optionally, further comprising at least one of:
(i) L, or modified form thereof, at at least one position corresponding to positions 85 or 98 of consensus SEQ ID NO: 905; and
(ii) a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at a position corresponding to position 85 of consensus SEQ ID NO: 905;
thereby producing a modified copepod luciferase polypeptide,wherein the modified polypeptide in (a) comprises at least one motif selected from the group consisting of:(i) a BCA motif at at least one position corresponding to conserved cysteines C5, C6, and C9; and
(ii) a BCA? motif at at least one position corresponding to conserved cysteines C5, C6, and C9; and
a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at the position corresponding to position 85 of consensus SEQ ID NO: 905;or in (b) comprises at least one motif selected from the group consisting of:(i) a BCA motif at at least one position corresponding to conserved cysteines C5 and C9; and
(ii) a BCA? motif at at least one position corresponding to conserved cysteines C5 and C9; and a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at the position corresponding to position 85 of consensus SEQ ID NO: 905.
US Pat. No. 10,426,782

PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR AND PROCESSES FOR THEIR PREPARATION

MILLENNIUM PHARMACEUTICAL...

1. A pharmaceutical composition comprising:(1) 10% to 50% w/w of a solid dispersion extrudate comprising:
(a) about 40% w/w of (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof, and
(b) about 60% w/w of copovidone; and
(2) 90% to 50% w/w of one or more pharmaceutically acceptable excipients,
wherein the solid dispersion extrudate comprises <3% w/w of (S)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide.
US Pat. No. 10,428,318

MUTATED SIALIDASES

1. A mutated ?2,6-transsialidase that comprises an amino acid sequence with at least 60% identity to SEQ ID No: 1, and further comprises at least one mutation selected from the group consisting of:at position 156, an amino acid selected from the group consisting of Ser, Thr, Cys, Tyr, Asn, Gln and Trp;
at position 161, an amino acid selected from the group consisting of Ala, Val, Ile, Leu, Phe, Tyr, Trp and Gly;
at position 180, an amino acid selected from the group consisting of Asp, Asn and Gln;
at position 186, an amino acid selected from the group consisting of Val, Ile, Leu, Met, Phe, Tyr, Trp, Ser, Cys and Thr;
at position 218, an amino acid selected from the group consisting of Val, Ile, Leu, Met, Phe, Tyr, Trp, Cys, Gly and Thr;
at position 222, an amino acid selected from the group consisting of Gin, Asp, Glu, Cys, Thr, Phe, Tyr, Trp, Arg, Lys and His;
at position 235, an amino acid selected from the group consisting of Arg, His, Ser, Cys, Ala, Val, Ile and Leu;
at position 242, an amino acid selected from the group consisting of Arg, His and Lys;
at position 261, an amino acid selected from the group consisting of His, Lys, Asp, Glu, Ala, Val, Leu and Phe;
at position 315, an amino acid selected from the group consisting of Ser, Thr and Cys;
at position 342, an amino acid selected from the group consisting of Ser and Cys, preferably Cys;
at position 349, an amino acid selected from the group consisting of Ser, Thr and Cys;
at position 350, an amino acid selected from the group consisting of Ser, Thr, Cys, Tyr, Trp and Phe;
at position 356, an amino acid selected from the group consisting of Ala, Val, Ile, Leu, Phe and Trp; and/or
at position 438, an amino acid selected from the group consisting of Arg, His and Lys,
wherein said mutated ?2,6-transsialidase has transsialidase and/or sialyltransferase activity with increased regioselectivity and/or increased thermostability compared to a parent ?2,6-transsialidase without the mutation.
US Pat. No. 10,426,783

THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE

KOWA COMPANY, LTD., Nago...

1. A method of treating ocular fundus disease comprising:administering an effective amount of an agent comprising (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof to a subject in need thereof,
wherein the ocular fundus disease is a diabetic macular edema or exudative age-related macular degeneration.
US Pat. No. 10,428,319

ENGINEERED CAS9 NUCLEASES

EDITAS MEDICINE, INC., C...

1. A polypeptide having nuclease activity, comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, wherein the polypeptide comprises an amino acid substitution at two or more of the following positions of SEQ ID NO:13: D23, T67, Y128, and D1251.
US Pat. No. 10,428,320

CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS AUTOLYSIN E, METHOD OF PRODUCING THE CRYSTAL AND ITS USE IN SCREENING METHODS

J. Stefan Institute, Lju...

1. A crystal comprising N-acetylglucosimindase autolysin E (AtlE) of Staphylococcus aureus (S. aureus), or fragment thereof, wherein said crystal is characterized by (a) the space group symmetry P212121 and (b) the unit cell dimensions of a=46.6 ?±1-2 ?, b=69.9 ?±1-2 ?,and c=73.3 ?±1-2 ?, with ?=90°, ?=90°, and ?=90°, and wherein said fragment is an N-terminal truncation of AtlE lacking the N-terminal transmembrane region.
US Pat. No. 10,428,321

ALPHA-AMYLASE VARIANTS

1. An alpha-amylase variant comprising:a) a deletion at two or more positions corresponding to positions R181, G182, D183 and G184 of the mature polypeptide of SEQ ID NO: 1,
b) a substitution at one or more positions corresponding to positions Y198, Y200, L201, Y203 and A204 of the mature polypeptide of SEQ ID NO: 1, and
c) a substitution of the methionine at the position corresponding to position M202 of the mature polypeptide of SEQ ID NO: 1,wherein the variant has at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1, and wherein the variant has alpha-amylase activity.
US Pat. No. 10,426,786

MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS

THE REGENTS OF THE UNIVER...

1. A method of preventing or terminating a seizure in a subject in need thereof, comprising administration to the subject of an effective amount of a benzodiazepine and allopregnanolone, wherein both of the benzodiazepine and the allopregnanolone are administered in a subtherapeutic dose, wherein the subject has been exposed to a nerve agent or a pesticide that can cause seizures.
US Pat. No. 10,428,322

HETEROLOGOUS EXPRESSION OF TERMITE CELLULASES IN YEAST

Lallemand Hungary Liquidi...

1. An isolated polynucleotide comprising a nucleic acid which encodes the mature endoglucanase of SEQ ID NO: 38, wherein said nucleic acid is codon-optimized for expression in a yeast strain wherein at least one nucleotide within a sequence of 4, 5, 6, 7, 8, 9, or 10 consecutive A, T, C or G nucleotides is replaced with a different nucleotide, wherein the nucleotide replacement does not alter the amino acid sequence encoded by the polynucleotide and wherein the nucleotide replacement creates a codon that is the second most frequently used codon to encode an amino acid in the yeast strain.
US Pat. No. 10,426,787

TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS

Bausch Health US, LLC, B...

1. A method of treating psoriasis, the method comprising topically applying a pharmaceutical composition to an affected area of a body of a subject suffering from psoriasis; wherein the composition comprises:(a) halobetasol propionate at a concentration of 0.01 percent by weight of the composition;
(b) tazarotene at a concentration of 0.045 percent by weight of the composition; and
(c) an aqueous dermatologically acceptable carrier comprising carbomer copolymer type B, carbomer homopolymer type A, and a liquid oil comprising diethyl sebacate and light mineral oil;
wherein said applying is carried out one or more times per day for a period of time sufficient to treat such psoriasis and
wherein the composition comprising the halobetasol propionate and the tazarotene at said concentrations is capable of providing synergistic efficacy and synergistic reduction of at least an adverse event selected from the group consisting of itching, burning, and stinging in said treating.
US Pat. No. 10,426,788

CHEMICAL ENTITIES THAT KILL SENESCENT CELLS FOR USE IN TREATING AGE-RELATED DISEASE

Unity Biotechnology, Inc....

1. A method of killing a senescent cell, the senescent cell being characterized as a non-cancerous cell in replicative arrest, the method comprising contacting the senescent cell with an effective amount of a senolytic compound that is lethal to the senescent cell, wherein the senolytic compound is gambogic acid or a pharmaceutical salt thereof.
US Pat. No. 10,428,324

ACOUSTIC MANIPULATION OF FLUIDS BASED ON EIGENFREQUENCY

TRIAD NATIONAL SECURITY, ...

1. A system for acoustic fluid manipulation, the system comprising:an acoustic resonator device comprising:
a fluid chamber that receives a volume of a fluid, the volume of the fluid including a phase-separate material, wherein one or more eigenfrequencies characterize at least the volume of the fluid;
a carrier surface forming at least a first sidewall portion of the fluid chamber;
a reflector surface forming at least a second sidewall portion of the fluid chamber; and
a transducer coupled to the carrier surface, wherein receipt of electricity at the transducer from a voltage source triggers emission of an acoustic output by the transducer, the acoustic output thereby passing through the carrier surface and the fluid chamber toward the reflector surface, the transmission of the acoustic wave thereby exciting at least the volume of the fluid; and
a controller configured to track the one or more eigenfrequencies over time in response to changes in one or more properties of the volume of the fluid and adjust the output frequency of the acoustic output by the transducer based on the one or more tracked eigenfrequencies,
wherein the controller is configured to adjust the output frequency toward a frequency that is near one of the one or more tracked eigenfrequencies and away from an eigenfrequency of the acoustic resonator device when the acoustic resonator device is empty.
US Pat. No. 10,426,789

ALLELE SPECIFIC MODULATORS OF P23H RHODOPSIN

1. A compound comprising (i) a modified oligonucleotide consisting of 16 to 30 linked nucleosides having a nucleobase sequence comprising any one of SEQ ID NOs: 15, 21, or 64, or (ii) a modified oligonucleotide consisting of 15 to 30 linked nucleosides having a nucleobase sequence comprising SEQ ID NO: 29.
US Pat. No. 10,428,326

METHODS AND SYSTEMS FOR DROPLET-BASED SINGLE CELL BARCODING

10X GENOMICS, INC., Plea...

1. A method for processing or analyzing one or more components from a cellular sample, comprising:(a) providing a plurality of cell beads and a plurality of barcode beads, wherein (i) a cell bead of said plurality of cell beads comprises a cell, wherein said cell comprises a nucleic acid molecule in an interior region of said cell, and (ii) a barcode bead of said plurality of barcode beads comprises a plurality of nucleic acid barcode molecules, wherein nucleic acid barcode molecules of said plurality of nucleic acid barcode molecules comprise a common barcode sequence;
(b) subjecting said plurality of cell beads to bulk processing, which bulk processing comprises: (i) rendering said nucleic acid molecule accessible to a species external to said interior region and (ii) denaturing said nucleic acid molecule to generate a denatured nucleic acid molecule in said cell bead; and
(c) partitioning said plurality of cell beads and said plurality of barcode beads into a plurality of partitions, wherein upon partitioning, a partition of said plurality of partitions comprises said cell bead and said barcode bead.
US Pat. No. 10,426,791

SYNERGISM OF GOS AND POLYFRUCTOSE

N.V. Nutricia, Zoetermee...

1. A method of treating eczema, the method consisting of orally administering to a mammal suffering from eczema a composition comprising galactooligosaccharide and polyfructose, wherein the weight ratio of galactooligosaccharide:polyfructose is 97:3 to 80:20, wherein the composition does not comprise lactobacilli.
US Pat. No. 10,428,327

COMPOSITIONS AND METHODS FOR ENHANCING HOMOLOGOUS RECOMBINATION

LIFE TECHNOLOGIES CORPORA...

1. A method for performing homologous recombination, the method comprising:(a) generating a double-stranded break in a nucleic acid molecule present inside a cell to produce a cleaved nucleic acid molecule, and
(b) contacting the cleaved nucleic acid molecule generated in (a) with a partially double-stranded donor nucleic acid molecule,
wherein the cleaved nucleic acid molecule and the donor nucleic acid molecule each contain matched termini on at least one end,
wherein the matched termini on at least one end of the cleaved nucleic acid molecule and on at least one end the donor nucleic acid molecule is at least ten nucleotides in length,
wherein the matched terminus on at least one end of the cleaved nucleic acid molecule is double-stranded and the matched terminus on at least one end of the donor nucleic acid molecule comprises a 3? single-stranded overhang.
US Pat. No. 10,426,792

AMINO ACID COMPOSITIONS

ThermoLife International,...

1. A composition or a supplement formulation for human ingestion comprising a nitrate of a compound selected from the group consisting of: carnitine, taurine, acetyl derivative of carnitine, acetyl derivative of taurine, propionyl derivative of carnitine, and propionyl derivative of taurine, wherein the nitrate is a salt of nitrate or a mixed salt of nitrate.
US Pat. No. 10,426,793

MEDICATION AND APPLICATION FOR TREATMENT OF HYPERTENSION BASED ON ANION AND TRADITIONAL CHINESE MEDICINE

1. A medicament for treatment of hypertension comprising: 9˜30% by percentage weight of Scutellaria baicalensis, 3˜9% by percentage weight of Radix Bupleuri, 3˜12% by percentage weight of Uncaria tomentosa (cat's claw), 3˜9% by percentage weight of Ginseng, 15˜25% by percentage weight of Cynanchum mooreanum Hemsl., 3˜9% by percentage weight of Cordyceps sinensis (Berk.) Sacc., 10˜15% by percentage weight of Flastem Milkvetch Seed, 9˜15% by percentage weight of Dermatocarpon miniatum (L.) Mann. [Lichen miniatius L.], 10˜15% by percentage weight of Millettia dielsiana, 10˜15% by percentage weight of stem or root of Dalbergia hancei Benth. (Leguminosae), 0.1˜1% by percentage weight of anion powder and 0.1˜1% by percentage weight of far-infrared nano powder, wherein the particle size of said anion powder and said far-infrared nano powder is 2000˜4000 mesh, and wherein said medicament for treatment of hypertension is in the form of a pill.
US Pat. No. 10,428,329

COMPOSITIONS AND METHODS USING CAPSIDS RESISTANT TO HYDROLASES

APSE, INC., St. Louis, M...

1. A method for producing double stranded RNA comprising (a) purifying from a bacterial lysate:a first composition comprising a virus-like particle (VLP) comprising protease resistant capsid proteins enclosing a heterologous cargo molecule, wherein the heterologous cargo molecule comprises a long single stranded sense RNA having more than 30 nucleotides, the cargo molecule further comprising a capsid specific packing sequence, and
a second composition comprising a VLP comprising protease resistant capsid proteins enclosing a heterologous cargo molecule, wherein the heterologous cargo molecule comprises a long single stranded antisense RNA complementary to the sense strand RNA of the first composition, said single stranded antisense RNA having more than 30 nucleotides, the cargo molecule further comprising a capsid specific packing sequence;
(b) mixing equal amounts of each composition;
(c) isolating the heterologous cargo molecules thereof;
(d) annealing the heterologous cargo molecules to form a double stranded RNA molecule;
(e) isolating the double stranded RNA molecule.
US Pat. No. 10,428,330

STEM-LOOP COMPOSITIONS AND METHODS FOR INHIBITING FACTOR D

Vitrisa Therapeutics, Inc...

1. An aptamer comprising a nucleic acid sequence that selectively binds to complement factor D (fD) and having a stem-loop secondary structure comprising, in a 5? to 3? direction, a first base-paired stem, a first loop, a second base-paired stem, a second loop, and a third loop, wherein said third loop comprises 6 or more nucleotides, non-nucleotidyl spacers, or a combination thereof, and wherein said third loop is adjacent to said first base-paired stem.
US Pat. No. 10,428,331

TARGETED NANOCARRIERS FOR THE ADMINISTRATION OF IMMUNOSUPPRESSIVE AGENTS

MUSC Foundation for Resea...

1. A targeted nanocarrier, comprising an effective amount of an immunosuppressive agent encapsulated in a micelle that comprises on its surface a peptide or peptidomimetic that binds Complement component 3 (C3) breakdown products and reperfusion epitopes, a peptide or peptidomimetic that binds an integrin, or a combination thereof, wherein the peptide or peptidomimetic that binds C3 breakdown products comprises a Complement Receptor type 2 (Cr2) peptide or peptidomimetic;wherein the peptide or peptidomimetic that binds an integrin comprises the amino acid sequence Arg-Gly-Asp (RGD); and
wherein the nanocarrier has a mean diameter of 10 nm to 15 nm.
US Pat. No. 10,426,796

COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME

SMART Surgical, Inc., Bo...

1. A composition for performing a medical therapy, comprising:a low pH fluid base, wherein the low pH fluid base comprises dextrose;
mononuclear cells obtained from human umbilical cord blood; and
albumin, wherein the concentration of albumin is between about 10 mg/ml and about 150 mg/ml, and wherein the composition is configured for implantation within a human subject.
US Pat. No. 10,428,332

HYBRID IMMUNOGLOBULINS WITH MOVING PARTS

1. A process of making a product comprising:a) transfecting a cell with a recombinant nucleic acid which encodes a chimeric polypeptide comprising, from its N terminus to its C terminus,
(i) an N-terminal signal sequence, contiguous with
(ii) such stretch of consecutive amino acids capable of forming a disulfide bond, contiguous with
(iii) a C-terminal intein-containing binding domain,
under conditions such that:
(i) the cell expresses the chimeric polypeptide;
(ii) the N-terminal signal sequence is cleaved from the chimeric polypeptide, so as to produce a second chimeric polypeptide comprising the stretch of consecutive amino acids that is capable of forming a disulfide bond contiguous with the C-terminal intein-containing binding domain; and
(iii) the cell secretes the second chimeric polypeptide,
b) isolating the secreted second chimeric polypeptide produced in step (a);
c) treating the second chimeric polypeptide from step (b) with a cysteine or selenocysteine, so as to cause:
(i) thio-mediated cleavage of the C-terminal intein-containing binding domain from the stretch of consecutive amino acids; and
(ii) ligation of the cysteine or selenocysteine to such stretch of consecutive amino acids within such second chimeric polypeptide, at the C-terminal side thereof;
d) recovering the product of step (c) which is the stretch of consecutive amino acids comprising at its C-terminal side the additional cysteine or selenocysteine, and
e) then either:
(i) combining the product recovered in step (d) with a second product made using the process of steps (a)-(d) under conditions resulting in the formation of an —S—S—, —S—Se—, —Se—Se—, or —Se—S— bond between the respective C-terminal residues of the first product and the second product;
(ii) combining the product recovered in step (d) with a second, different stretch of consecutive amino acids comprising an N-terminal S-terminus or Se-terminus, under conditions resulting in the formation of an —S—S—, —S—Se—, —Se—Se—, or —Se—S— bond between the C terminus of the product and the N-terminal S-terminus or Se-terminus of the second, different stretch of consecutive amino acids; or
(iii) combining the product recovered in step (d) with a solid surface under conditions resulting in attachment of the product to such surface at its C-terminus, wherein the attachment is mediated by an —S—S—, —S—Se—, —Se—Se—, or —Se—S— bond formed between the cysteine or selenocysteine of the product and a cysteine or selenocysteine of the solid surface.